TWI731153B - 用於治療神經性起立性低血壓之化合物 - Google Patents
用於治療神經性起立性低血壓之化合物 Download PDFInfo
- Publication number
- TWI731153B TWI731153B TW106129248A TW106129248A TWI731153B TW I731153 B TWI731153 B TW I731153B TW 106129248 A TW106129248 A TW 106129248A TW 106129248 A TW106129248 A TW 106129248A TW I731153 B TWI731153 B TW I731153B
- Authority
- TW
- Taiwan
- Prior art keywords
- patient
- compound
- piperidine
- phenyl
- trifluorophenoxymethyl
- Prior art date
Links
- 208000001089 Multiple system atrophy Diseases 0.000 title claims abstract description 63
- 206010031127 Orthostatic hypotension Diseases 0.000 title claims abstract description 29
- 230000001272 neurogenic effect Effects 0.000 title claims abstract description 17
- 150000001875 compounds Chemical class 0.000 title claims description 74
- TZIALEBTHQWNAO-UHFFFAOYSA-N ampreloxetine Chemical compound FC1=CC(F)=CC(F)=C1OCC1=CC=CC=C1C1CCNCC1 TZIALEBTHQWNAO-UHFFFAOYSA-N 0.000 claims abstract description 72
- 150000003839 salts Chemical class 0.000 claims abstract description 61
- 208000024891 symptom Diseases 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims description 78
- 208000018737 Parkinson disease Diseases 0.000 claims description 34
- 208000002173 dizziness Diseases 0.000 claims description 33
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 32
- 230000002567 autonomic effect Effects 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 239000013078 crystal Substances 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 16
- 230000035488 systolic blood pressure Effects 0.000 claims description 15
- RVUPIJWDTBFULZ-UHFFFAOYSA-N 4-[2-[(2,4,6-trifluorophenoxy)methyl]phenyl]piperidine;hydrochloride Chemical compound Cl.FC1=CC(F)=CC(F)=C1OCC1=CC=CC=C1C1CCNCC1 RVUPIJWDTBFULZ-UHFFFAOYSA-N 0.000 claims description 14
- 208000009144 Pure autonomic failure Diseases 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 9
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 7
- 230000008018 melting Effects 0.000 claims description 7
- 238000002844 melting Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000013433 lightheadedness Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 description 41
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 34
- 239000003795 chemical substances by application Substances 0.000 description 28
- 230000000694 effects Effects 0.000 description 23
- 241000700159 Rattus Species 0.000 description 20
- 102000019208 Serotonin Plasma Membrane Transport Proteins Human genes 0.000 description 20
- 108010012996 Serotonin Plasma Membrane Transport Proteins Proteins 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 239000003826 tablet Substances 0.000 description 18
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 17
- 238000000034 method Methods 0.000 description 17
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 17
- 235000019439 ethyl acetate Nutrition 0.000 description 16
- 239000007937 lozenge Substances 0.000 description 16
- 229960002748 norepinephrine Drugs 0.000 description 16
- -1 pamoate (pamoate) Chemical compound 0.000 description 16
- 229940068196 placebo Drugs 0.000 description 16
- 239000000902 placebo Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 239000002775 capsule Substances 0.000 description 14
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 13
- 230000036772 blood pressure Effects 0.000 description 13
- 238000011156 evaluation Methods 0.000 description 13
- 238000009472 formulation Methods 0.000 description 13
- 229960003732 tyramine Drugs 0.000 description 13
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 206010020772 Hypertension Diseases 0.000 description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 229940016286 microcrystalline cellulose Drugs 0.000 description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 11
- 239000008108 microcrystalline cellulose Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 206010061666 Autonomic neuropathy Diseases 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 210000003403 autonomic nervous system Anatomy 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 231100000673 dose–response relationship Toxicity 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 9
- 229960002430 atomoxetine Drugs 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 210000000278 spinal cord Anatomy 0.000 description 9
- PTKSEFOSCHHMPD-SNVBAGLBSA-N 2-amino-n-[(2s)-2-(2,5-dimethoxyphenyl)-2-hydroxyethyl]acetamide Chemical compound COC1=CC=C(OC)C([C@H](O)CNC(=O)CN)=C1 PTKSEFOSCHHMPD-SNVBAGLBSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 206010044565 Tremor Diseases 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 238000000576 coating method Methods 0.000 description 8
- 239000007903 gelatin capsule Substances 0.000 description 8
- 229960001094 midodrine Drugs 0.000 description 8
- 229940100688 oral solution Drugs 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 7
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 229920002472 Starch Polymers 0.000 description 7
- 235000015197 apple juice Nutrition 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 206010042772 syncope Diseases 0.000 description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 6
- 108010078791 Carrier Proteins Proteins 0.000 description 6
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 230000009102 absorption Effects 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000006872 improvement Effects 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000002390 rotary evaporation Methods 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108010010803 Gelatin Proteins 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 5
- 239000004698 Polyethylene Substances 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000035487 diastolic blood pressure Effects 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 208000001953 Hypotension Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 102000003802 alpha-Synuclein Human genes 0.000 description 4
- 108090000185 alpha-Synuclein Proteins 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 229960005070 ascorbic acid Drugs 0.000 description 4
- 210000003169 central nervous system Anatomy 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- SYWHXTATXSMDSB-GSLJADNHSA-N fludrocortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O SYWHXTATXSMDSB-GSLJADNHSA-N 0.000 description 4
- 229960003336 fluorocortisol acetate Drugs 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000036543 hypotension Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 229960001375 lactose Drugs 0.000 description 4
- 239000008297 liquid dosage form Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 230000001144 postural effect Effects 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 235000010356 sorbitol Nutrition 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 3
- 102000008092 Norepinephrine Plasma Membrane Transport Proteins Human genes 0.000 description 3
- 108010049586 Norepinephrine Plasma Membrane Transport Proteins Proteins 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000001919 adrenal effect Effects 0.000 description 3
- 239000000533 adrenergic alpha-1 receptor agonist Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 239000008365 aqueous carrier Substances 0.000 description 3
- 210000000467 autonomic pathway Anatomy 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 229960002728 midodrine hydrochloride Drugs 0.000 description 3
- MGCQZNBCJBRZDT-UHFFFAOYSA-N midodrine hydrochloride Chemical compound [H+].[Cl-].COC1=CC=C(OC)C(C(O)CNC(=O)CN)=C1 MGCQZNBCJBRZDT-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 3
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000002889 sympathetic effect Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- WSEQXVZVJXJVFP-UHFFFAOYSA-N 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile Chemical compound O1CC2=CC(C#N)=CC=C2C1(CCCN(C)C)C1=CC=C(F)C=C1 WSEQXVZVJXJVFP-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 2
- QQFWMPUXPLBWTG-UHFFFAOYSA-N 2,4,6-trifluorophenol Chemical compound OC1=C(F)C=C(F)C=C1F QQFWMPUXPLBWTG-UHFFFAOYSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- NFDRERGZXAAWQK-UHFFFAOYSA-N 4-[2-(hydroxymethyl)phenyl]piperidine-1-carboxylic acid Chemical compound OCC1=CC=CC=C1C1CCN(C(O)=O)CC1 NFDRERGZXAAWQK-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 208000019505 Deglutition disease Diseases 0.000 description 2
- 102000006441 Dopamine Plasma Membrane Transport Proteins Human genes 0.000 description 2
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- 208000034347 Faecal incontinence Diseases 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- 101000639975 Homo sapiens Sodium-dependent noradrenaline transporter Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 101100041796 Rattus norvegicus Slc6a4 gene Proteins 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 101710164184 Synaptic vesicular amine transporter Proteins 0.000 description 2
- 102100034333 Synaptic vesicular amine transporter Human genes 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 239000000048 adrenergic agonist Substances 0.000 description 2
- 239000000674 adrenergic antagonist Substances 0.000 description 2
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 2
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 229960004977 anhydrous lactose Drugs 0.000 description 2
- 230000004872 arterial blood pressure Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 210000005080 cortical synaptosome Anatomy 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000008406 drug-drug interaction Effects 0.000 description 2
- 206010013781 dry mouth Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000002329 esterase inhibitor Substances 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229960002011 fludrocortisone Drugs 0.000 description 2
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940093181 glucose injection Drugs 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 102000055827 human SLC6A2 Human genes 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- TUESWZZJYCLFNL-UHFFFAOYSA-N hydroxystilbamidine Chemical compound C1=CC(C(=N)N)=CC=C1C=CC1=CC=C(C(N)=N)C=C1O TUESWZZJYCLFNL-UHFFFAOYSA-N 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- 210000004731 jugular vein Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 235000011007 phosphoric acid Nutrition 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000006069 physical mixture Substances 0.000 description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 2
- 238000001144 powder X-ray diffraction data Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 2
- 229960002290 pyridostigmine Drugs 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000003938 response to stress Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000000646 scanning calorimetry Methods 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000003568 synaptosome Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- YBTSAJAGHUIYNE-UHFFFAOYSA-N tert-butyl 4-[2-[(2,4,6-trifluorophenoxy)methyl]phenyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=CC=CC=C1COC1=C(F)C=C(F)C=C1F YBTSAJAGHUIYNE-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000011179 visual inspection Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- QXWYKJLNLSIPIN-YUMQZZPRSA-N (2s,3s)-2-azaniumyl-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-YUMQZZPRSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- UHTQHHLSGVOGQR-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-4-ium-1-yl]ethanesulfonate Chemical compound OCCN1CCN(CCS(O)(=O)=O)CC1.OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 UHTQHHLSGVOGQR-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- ITJNARMNRKSWTA-RLXJOQACSA-N 3-(2-methoxyphenoxy)-3-phenyl-n-(tritritiomethyl)propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC([3H])([3H])[3H])OC1=CC=CC=C1OC ITJNARMNRKSWTA-RLXJOQACSA-N 0.000 description 1
- SQVIAVUSQAWMKL-UHFFFAOYSA-N 3-[2-(ethylamino)-1-hydroxyethyl]phenol Chemical compound CCNCC(O)C1=CC=CC(O)=C1 SQVIAVUSQAWMKL-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 1
- KXUVOOVIGIJFNL-UHFFFAOYSA-N 4-[2-[(2-fluorophenoxy)methyl]phenyl]piperidine Chemical class FC1=CC=CC=C1OCC1=CC=CC=C1C1CCNCC1 KXUVOOVIGIJFNL-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- BNNMDMGPZUOOOE-UHFFFAOYSA-N 4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1 BNNMDMGPZUOOOE-UHFFFAOYSA-N 0.000 description 1
- PFBZWBJAFXWUSF-UHFFFAOYSA-N 5-ht 5-hydroxytryptamine Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1.C1=C(O)C=C2C(CCN)=CNC2=C1 PFBZWBJAFXWUSF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 206010070883 Alien limb syndrome Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010005063 Bladder pain Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- NPCVCMYXJYLPLK-UHFFFAOYSA-N C(CCCCCCCCCCC)S(=O)(=O)O.C(CCCCCCCCCCC)S(=O)(=O)O Chemical compound C(CCCCCCCCCCC)S(=O)(=O)O.C(CCCCCCCCCCC)S(=O)(=O)O NPCVCMYXJYLPLK-UHFFFAOYSA-N 0.000 description 1
- WUVNUFSCTADJFL-UHFFFAOYSA-N C1(=CC=CC=2C(=CC=CC12)S(=O)(=O)O)S(=O)(=O)O.C1(=CC=CC=2C(=CC=CC12)S(=O)(=O)O)S(=O)(=O)O Chemical compound C1(=CC=CC=2C(=CC=CC12)S(=O)(=O)O)S(=O)(=O)O.C1(=CC=CC=2C(=CC=CC12)S(=O)(=O)O)S(=O)(=O)O WUVNUFSCTADJFL-UHFFFAOYSA-N 0.000 description 1
- DKJVKXICAKEMHJ-UHFFFAOYSA-N C1=C(C=CC2=CC(=CC=C12)S(=O)(=O)O)S(=O)(=O)O.C1=C(C=CC2=CC(=CC=C12)S(=O)(=O)O)S(=O)(=O)O Chemical compound C1=C(C=CC2=CC(=CC=C12)S(=O)(=O)O)S(=O)(=O)O.C1=C(C=CC2=CC(=CC=C12)S(=O)(=O)O)S(=O)(=O)O DKJVKXICAKEMHJ-UHFFFAOYSA-N 0.000 description 1
- 206010071601 CYP2D6 polymorphism Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009696 Clumsiness Diseases 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012645 Diabetic autonomic neuropathy Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 229940122601 Esterase inhibitor Drugs 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 206010056696 Gaze palsy Diseases 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000008017 Hypohidrosis Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 206010027566 Micturition urgency Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010068786 Overlap syndrome Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 description 1
- 206010035039 Piloerection Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010071390 Resting tremor Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000009106 Shy-Drager Syndrome Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000004301 Sinus Arrhythmia Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 241000009298 Trigla lyra Species 0.000 description 1
- 206010045178 Tunnel vision Diseases 0.000 description 1
- 206010067895 Tyramine reaction Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- WERKSKAQRVDLDW-ANOHMWSOSA-N [(2s,3r,4r,5r)-2,3,4,5,6-pentahydroxyhexyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO WERKSKAQRVDLDW-ANOHMWSOSA-N 0.000 description 1
- GDXWHFPKFUYWBE-UHFFFAOYSA-N [F].Cl Chemical compound [F].Cl GDXWHFPKFUYWBE-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000004598 abnormal eye movement Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 1
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 206010002512 anhidrosis Diseases 0.000 description 1
- 230000037001 anhydrosis Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000002181 anti-sympathetic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 231100000877 autonomic nervous system dysfunction Toxicity 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000035581 baroreflex Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- MCQRPQCQMGVWIQ-UHFFFAOYSA-N boron;methylsulfanylmethane Chemical compound [B].CSC MCQRPQCQMGVWIQ-UHFFFAOYSA-N 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229940006460 bromide ion Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- VFRCNXKYZVQYLX-UHFFFAOYSA-N deglymidodrine Chemical compound COC1=CC=C(OC)C(C(O)CN)=C1 VFRCNXKYZVQYLX-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002804 dopamine agent Substances 0.000 description 1
- 108700006189 dopamine beta hydroxylase deficiency Proteins 0.000 description 1
- 208000009308 dopamine beta-hydroxylase deficiency Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229960001104 droxidopa Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229960004695 etilefrine Drugs 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000009454 functional inhibition Effects 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229960005219 gentisic acid Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 229920001903 high density polyethylene Polymers 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000004700 high-density polyethylene Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SYJRVVFAAIUVDH-UHFFFAOYSA-N ipa isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229940080526 mannitol injection Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 150000001247 metal acetylides Chemical class 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- ITJNARMNRKSWTA-UHFFFAOYSA-N nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 description 1
- 229950004211 nisoxetine Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940100629 oral lozenge Drugs 0.000 description 1
- 229960005010 orotic acid Drugs 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229960001779 pargyline Drugs 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- OYSBZLVHMPNJMR-UHFFFAOYSA-N pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.OC(=O)C1=CC=CN=C1 OYSBZLVHMPNJMR-UHFFFAOYSA-N 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000011172 small scale experimental method Methods 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940071103 sulfosalicylate Drugs 0.000 description 1
- NGLNQYUCGINPIR-UHFFFAOYSA-N sulfuric acid 4-[2-[(2,4,6-trifluorophenoxy)methyl]phenyl]piperidine Chemical compound OS(O)(=O)=O.Fc1cc(F)c(OCc2ccccc2C2CCNCC2)c(F)c1 NGLNQYUCGINPIR-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- XUAIUEGHJIVPSA-UHFFFAOYSA-N tert-butyl 4-[2-(hydroxymethyl)phenyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=CC=CC=C1CO XUAIUEGHJIVPSA-UHFFFAOYSA-N 0.000 description 1
- GZQANEQAVXGDBX-UHFFFAOYSA-N tert-butyl 4-[2-(methylsulfonyloxymethyl)phenyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1C1=CC=CC=C1COS(C)(=O)=O GZQANEQAVXGDBX-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- IDELNEDBPWKHGK-UHFFFAOYSA-N thiobutabarbital Chemical compound CCC(C)C1(CC)C(=O)NC(=S)NC1=O IDELNEDBPWKHGK-UHFFFAOYSA-N 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000005591 trimellitate group Chemical group 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000006438 vascular health Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- QUSLQENMLDRCTO-YJNKXOJESA-N win 35428 Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@H]2C(=O)OC)=CC=C(F)C=C1 QUSLQENMLDRCTO-YJNKXOJESA-N 0.000 description 1
- GQDDNDAYOVNZPG-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C[C]2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3N=C21 GQDDNDAYOVNZPG-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本發明係關於一種以4-[2-(2,4,6-三氟苯氧基甲基)-苯基]哌啶或其醫藥上可接受之鹽於治療神經性起立性低血壓或其症狀之用途。
Description
本發明係關於一種以4-[2-(2,4,6-三氟苯氧基甲基)-苯基]哌啶或其醫藥上可接受之鹽於治療神經性起立性低血壓或其症狀之用途。
起立性低血壓(OH)(亦稱為姿勢性低血壓)為當人站起來時發生的低血壓形式。在醫學術語中,OH定義為在自仰臥至直立位置之姿勢變化的三分鐘內的至少20 mm Hg之收縮壓或至少10 mm Hg之舒張壓之落差(Neurology 1996;46:1470)。OH可產生多種症狀,包括眩暈、頭暈及暈厥(昏厥)。由於該等症狀的緣故,故OH通常減少或甚至妨礙需要站立或行走之日常活動。另外,OH與致病率及死亡率之增加相關聯。參見,例如,Jones等人,Expert Review of Cardiovascular Therapy,2015;13:11,1263-1276;Kuritzky等人,Postgrad. Med. 2015;127(7):702-715;及Low等人,J. Clin. Neurol.,2015;11(3):220-226。 OH之根本原因可廣義地分為神經性及非神經性類別。神經性起立性低血壓(nOH)為OH之與神經系統有關之形式,例如,由周邊或中樞神經病症諸如原發性自主神經衰竭(包括單純性自主神經衰竭、多發性系統萎縮症及帕金森氏症)及自主神經性病變(自主神經機能障礙)(包括糖尿病性及非糖尿病性自主神經性病變)(Arbique等人,JAMDA15
(2014) 234-239)引起之OH。該等病症可引起正腎上腺素(其為回應於姿勢改變而調節血壓之主要神經傳遞質)之缺乏或失調(Loavenbruck等人,Curr. Med. Res. Opin.,2015;31
:2095-2104)。因此,自主神經系統在姿勢改變期間無法適當地調節血壓及患者經歷顯著血壓差而導致例如眩暈、頭暈或暈厥。 因此,nOH治療的一個目標係增加患者中正腎上腺素之濃度。增加正腎上腺素濃度之一種方法係投與產生正腎上腺素之藥劑。例如,屈西多巴(droxidopa)(L-蘇式-3-4-二羥基苯基絲胺酸)為一種胺基酸,其係在中樞及周邊神經系統中藉由脫羧作用轉化為正腎上腺素,藉此增加正腎上腺素濃度(Kaufmann等人,Circulation,2003;108
:724-728;Kaufmann,Clin. Auton. Res.(2008)18
[Suppl 1]:19-24);及Isaacson等人,Vascular Health and Risk Management,2014,10
:169-176)。在美國,屈西多巴已核准用於治療罹患因原發性自主神經衰竭(帕金森氏症、多發性系統萎縮症及單純性自主神經衰竭)、多巴胺β-羥化酶缺少症及非糖尿病性自主神經病變引起的症狀性nOH之成年患者起立性眩暈、頭暈或「感覺快要漆黑的感覺」。屈西多巴的主要副作用係臥位高血壓及在處方資訊中因為該嚴重副作用而對該藥物有一黑框警語。 或者,患者的正腎上腺素濃度可藉由抑制造成正腎上腺素再吸收結果的正腎上腺素轉運體來增加。例如,阿托西汀(atomoxetine)為在美國已核准用於治、注意力缺陷過動症(ADHD)之選擇性正腎上腺素再吸收抑制劑。已證實阿托西汀會增加罹患中樞性自主神經衰竭的患者之血壓(Ramirez等人,Hypertension,2014;64
:1235-40;及Shibao等人,Hypertension,2007;50
:47-53)。然而,阿托西汀主要藉由CYP2D6酶通道代謝及因此其藥物動力學性質可根據個體是否具有減少之CYP2D6活性(不良代謝型)或正常CYP2D6活性(廣泛性代謝型)改變(Ring等人,Drug Metabolism and Distribution,2002,30
:319-323)。阿托西汀之處方資訊亦包括關於可能藥物-藥物相互作用之許多警語。此外,當用於治療ADHD時,阿托西汀與多種胃腸道不良作用(包括口乾及噁心)相關聯。阿托西汀尚未被批准用於nOH之治療。 用於治療nOH之其他藥劑包括α1-腎上腺素受體激動劑米多君(midodrine)(及其活性代謝產物去糖米多君(desglymidodrine));合成性鹽皮質激素(mineralocortidoid)氟氫可的松;及膽鹼酯酶抑制吡斯的明(pyridostigmine)。該等藥劑之副作用可包括就米多君而言之臥位高血壓、感覺異常(包括頭皮麻刺痛)、毛髮直立(雞皮疙瘩(goose bumps))及尿急或閉尿;就氟氫可的松而言之低鉀血症、頭痛、周邊水腫、心力衰竭及臥位高血壓;及就吡斯的明而言之腹部不適及尿急。 因此,希望具有可用於治療nOH之其他選項。特定言之,希望提供一種具有可預測藥物動力學性質之用於nOH治療之安全且具良好耐受性之正腎上腺素轉運體抑制劑。此外,由於臥位高血壓常見於nOH患者中及現存藥物中許多可引起或加劇臥位高血壓,故極度希望提供用於治療nOH之不引起或加劇臥位高血壓之化合物。 美國專利第8,304,432 B2號及第8,604,058 B2號揭示4-[2-(2-氟苯氧基甲基)苯基]哌啶化合物,其為血清素及正腎上腺素再吸收抑制劑。揭示於該等專利中之一種具體化合物為4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶,其具有式:。 該化合物亦稱為TD-9855。此外,美國專利第8,304,433 B2號及第9,073,859 B2號揭示4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶之鹽酸鹽結晶。該等專利揭示4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶之各種用途,包括治療疼痛病症、憂鬱病症、認知病症、壓力性尿失禁、慢性疲勞症候群、肥胖、與停經相關聯的血管舒縮性症狀、慢性下腰痛、骨關節炎及其他病症。該等專利未揭示4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶於治療nOH之用途;然而,與TD-9855在nOH中之2期試驗有關的資訊在2016年3月9日公開於ClinicalTrials.gov上。
本發明係關於一種以4-[2-(2,4,6-三氟苯氧基甲基)-苯基]哌啶或其醫藥上可接受之鹽於治療神經性起立性低血壓或其症狀之用途。 因此,在一個態樣中,本發明係關於式I之化合物:或其醫藥上可接受之鹽,其係用於治療人類患者神經性起立性低血壓;其中該化合物係以在約1 mg/天至約20 mg/天範圍內的量投與患者及其中該用途之特徵在於(a)患者坐式收縮壓之增加;(b)患者站立時間之增加;或(c)患者所經歷暈眩或頭暈之減少。在一個實施例中,該用途之特徵在於患者坐式收縮壓之增加。在另一個實施例中,該用途之特徵在於患者站立時間之增加。在另一個實施例中,該用途之特徵在於患者所經歷暈眩或頭暈之減少。 在另一個態樣中,本發明係關於式I化合物或其醫藥上可接受之鹽,其係用於增加罹患症狀性神經性起立性低血壓之人類患者之坐式收縮壓。 在另一個態樣中,本發明係關於式I化合物或其醫藥上可接受之鹽,其係用於增加罹患症狀性神經性起立性低血壓之人類患者之站立時間。 在另一個態樣中,本發明係關於式I化合物或其醫藥上可接受之鹽,其係用於治療人類患者之由症狀性神經性起立性低血壓引起的起立性眩暈或頭暈。 在另一個態樣中,本發明係關於包含醫藥上可接受之載劑及式I化合物或其醫藥上可接受之鹽之醫藥組合物,其係用於治療人類患者之神經性起立性低血壓;其中該組合物係經投與患者以提供在約1 mg/天至約20 mg/天範圍內的量之化合物及其中該用途之特徵在於(a)患者坐式收縮壓之增加;(b)患者站立時間之增加;或(c)患者所經歷暈眩或頭暈之減少。 在另一個態樣中,本發明係關於一種以式I化合物或其醫藥上可接受之鹽於製造用於治療人類患者神經性起立性低血壓的藥物中之用途;其中該化合物係以在約1 mg/天至約20 mg/天範圍內的量投與患者及其中該用途之特徵在於(a)患者坐式收縮壓之增加;(b)患者站立時間之增加;或(c)患者所經歷暈眩或頭暈之減少。 在另一個態樣中,本發明係關於一種用於治療人類患者神經性起立性低血壓之方法,該方法包括對患者投與式I化合物或其醫藥上可接受之鹽。 在另一個態樣中,本發明係關於一種用於治療人類患者神經性起立性低血壓之方法,該方法包括對患者投與式I化合物或其醫藥上可接受之鹽;其中該化合物係以約1 mg/天至約20 mg/天的量投與患者及其中該方法之特徵在於(a)患者坐式收縮壓之增加;(b)患者站立時間之增加;或(c)患者所經歷暈眩或頭暈之減少。 除非另有說明,否則以下單獨及相異實施例可應用於本發明之述於本文中之每一態樣。 在一個實施例中,該化合物為4-[2-(2,4,6-三氟苯氧基-甲基)苯基]哌啶鹽酸鹽。 在一個實施例中,該化合物為4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶之鹽酸鹽結晶,其特徵係包括在4.44±0.20、10.22±0.20、17.16±0.20及21.78±0.20之2θ值處之繞射峰之粉末x射線繞射圖案。在另一個實施例中,該4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶之鹽酸鹽結晶之另一特徵係在選自8.11±0.20、13.18±0.20、16.06±0.20、18.38±0.20、23.76±0.20、26.32±0.20、27.24±0.20、29.60±0.20及31.94±0.20之2θ值處具有一或多個其他繞射峰。 在一個實施例中,該化合物為4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶之鹽酸鹽結晶,其特徵係具有約197±2℃之熔點之差示掃描量熱法跡線。 在一個實施例中,該患者罹患選自原發性自主神經衰竭(包括單純性自主神經衰竭、多發性系統萎縮症及帕金森氏症);自主神經病變(包括糖尿病性及非糖尿病性自主神經病變)之神經疾病。在一個實施例中,該患者罹患原發性自主神經衰竭。在另一個實施例中,該患者罹患自主神經病變。在另一個實施例中,該患者罹患帕金森氏症。在一個特定實施例中,該患者罹患多發性系統萎縮症。 在一個實施例中,該化合物係以在約0.5 mg/天至約20 mg/天範圍內的量投與。在另一個實施例中,該化合物係以在約1 mg/天至約20 mg/天範圍內的量投與。在另一個實施例中,該化合物係以在約1 mg/天至約10 mg/天範圍內的量投與。在另一個實施例中,該化合物係以選自約1、2、3、4、5、6、7、8、9及10 mg/天的量投與。 在一個實施例中,該化合物係每天一次投與。 在一個實施例中,該化合物係呈包含醫藥上可接受之載劑及式I化合物或其醫藥上可接受之鹽之醫藥組合物形式投與。 在一個實施例中,該化合物係與選自α1-腎上腺素受體激動劑、α2-腎上腺素受體拮抗劑、皮質類固醇、正腎上腺素前驅物及膽鹼酯酶抑制劑;或其組合之藥劑一起投與。在一個特定實施例中,該化合物係與米多君、乙酸氟氫可的松、屈西多巴或吡斯的明或在各情況下其醫藥上可接受之鹽;諸如米多君鹽酸鹽或溴吡斯的明一起投與。 本文揭示本發明之其他態樣及實施例。
在本發明各種態樣及實施例中,本發明係關於一種以4-[2-(2,4,6-三氟苯氧基甲基)-苯基]哌啶或其醫藥上可接受之鹽於治療神經性起立性低血壓或其症狀之用途。 定義 當描述本發明時,除非另有指示,否則以下術語具有以下定義。 除非使用語境中另有明確指示,否則單數術語「一」、「一個」及「該」包括相應複數術語。 術語「約」意指指定值的±5%。 術語「熔點」意指藉由差示掃描量熱法觀測到對應於固相-至-液相變化之熱轉化之最大吸熱熱流時的溫度。 術語「醫藥上可接受」意指就投與患者而言係可接受的(例如,就指定用途而言具有可接受的安全性)。 術語「醫藥上可接受之鹽」意指由酸及鹼(包括兩性離子)製備之就投與患者(例如,就所給給藥方案而言具有可接受之安全性的鹽)而言可接受之鹽。 術語「治療有效量」意指當投與需要治療的患者時足以實現治療的量,例如,達成所期治療效果所需要的量。 術語「治療」意指改善或抑制所治療的醫學病症或失調症;或緩解醫學病症或異常之症狀。 術語「單位劑型」或「單位劑量」意指適合投與患者之物理上離散單元,即,各單元僅包含經計算以產生治療效應的預定量的治療劑或其與一或多個其他單元之組合。實例包括膠囊、錠劑及類似物。 用於本文中之所有其他術語欲具有其為具有熟習其等所屬一般技術者所瞭解之一般含義。 式I之化合物 本發明使用4-[2-(2,4,6-三氟苯氧基甲基)苯基]-哌啶,其具有式I:或其醫藥上可接受之鹽。 可依本文實例中所述或藉由揭示於美國專利第8,304,432 B2號;第8,304,433 B2號;及第8,247,433 B2號;及相關專利中之方法及程序來製備4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶。 在一個實施例中,4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶係以醫藥上可接受之鹽之形式使用。代表性醫藥上可接受之鹽包括以下酸(與圓括號中所示的對應陰離子)之鹽:乙酸(乙酸根)、抗壞血酸(抗壞血酸根)、苯磺酸(苯磺酸根)、苯甲酸(苯甲酸根)、樟腦磺酸(樟腦磺酸根)、氯茶鹼(氯茶鹼離子)、檸檬酸(檸檬酸根)、乙磺酸(乙磺酸根)、乙二磺酸(乙二磺酸根)、富馬酸(富馬酸根)、龍膽酸(龍膽酸根)、葡萄糖酸(葡萄糖酸根)、葡糖醛酸(葡糖醛酸根)、葡庚糖酸(葡庚糖酸根)、麩胺酸(麩胺酸根)、馬尿酸(馬尿酸根)、氫溴酸(溴離子)、鹽酸(氯離子)、氫碘酸(碘離子)、羥乙磺酸(羥乙磺酸根)、乳酸(乳酸根)、乳糖酸(乳糖酸根)、月桂基磺酸(月桂基磺酸根)、馬來酸(馬來酸根)、蘋果酸(蘋果酸根)、杏仁酸(杏仁酸根)、甲磺酸(甲磺酸根)、甲基磺酸(甲基磺酸根)、黏酸(黏酸根)、萘磺酸(萘磺酸根)、萘-1,5-二磺酸(萘-1,5-二磺酸根)、萘-2,6-二磺酸(萘-2,6-二磺酸根)、萘甲酸(萘甲酸根)、菸鹼酸(菸鹼酸根)、硝酸(硝酸根)、十八酸(十八酸根)、油酸(油酸根)、乳清酸(乳清酸根)、草酸(草酸根)、撲酸(撲酸根)、泛酸(泛酸根)、磷酸(磷酸根)、多聚半乳糖醛酸(多聚半乳糖醛酸根)、琥珀酸(琥珀酸根)、磺基水楊酸(磺基水楊酸根)、硫酸(硫酸根)、酒石酸(酒石酸根)、對甲苯磺酸(對甲苯磺酸根)及羥萘甲酸(羥萘甲酸根)、及類似者。該等鹽有時稱為酸加成鹽。 該等鹽可藉由使1莫耳當量之4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶與醫藥上可接受之酸中的約0.95至約1.05莫耳當量之酸性質子接觸來製備。例如,可使1莫耳當量之4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶與約1莫耳當量之鹽酸接觸以形成4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶鹽酸鹽;或可使1莫耳當量之4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶與約0.5莫耳當量之硫酸接觸以形成4-[2-(2,4,6-三氟苯氧基甲基)苯基]-哌啶硫酸鹽。 該等反應通常係在稀釋劑(諸如二氯甲烷、乙醇、乙酸乙酯、乙酸異丙酯及類似者)中,在約-20℃至約50℃範圍內的溫度下進行約0.5至約12小時或直到反應實質上完成。在反應完成時,通常,使用習知程序,諸如過濾、層析、再結晶及類似者單離產物。該等反應之產物可為結晶或可不為結晶。 在一個實施例中,用於本發明中之化合物為4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶鹽酸鹽。在另一個實施例中,該化合物為結晶4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶鹽酸鹽,其特徵係經表徵包括在4.44±0.20、10.22±0.20、17.16±0.20及21.78±0.20之2θ值處之繞射峰之粉末x射線。在另一個實施例中,該鹽酸鹽結晶之另一特徵係在選自8.11±0.20、13.18±0.20、16.06±0.20、18.38±0.20、23.76±0.20、26.32±0.20、27.24±0.20、29.60±0.20及31.94±0.20之2θ值處具有一或多個其他繞射峰。在另一個實施例中,該化合物為結晶4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶鹽酸鹽,其特徵係具有約197±2℃之熔點之差示掃描量熱法跡線。 可如本文實例中所述或藉由揭示於美國專利第8,304,432 B2號;第8,304,433 B2號;及第8,247,433 B2號;及相關專利中之方法及程序來製備用於本發明中之4-[2-(2,4,6-三氟苯氧基甲基)-苯基]哌啶之鹽酸鹽結晶。 醫藥組合物、調配物及劑型 在用於本發明中時,4-[2-(2,4,6-三氟苯氧基甲基)苯基]-哌啶或其醫藥上可接受之鹽通常係呈醫藥組合物或調配物形式投與患者。在論述本文組合物或調配物時,4-[2-(2,4,6-三氟苯氧基甲基)苯基]-哌啶或其醫藥上可接受之鹽可稱為「活性劑」以區分其與調配物之其他組分(諸如載劑或賦形劑)。因此,術語「活性劑」包括4-[2-(2,4,6-三氟苯氧基甲基)-苯基]哌啶及其醫藥上可接受之鹽。此外,除非另有指示,否則術語「載劑」及「賦形劑」在本文中可互換使用且具有相同含義。 本發明之醫藥組合物通常包含治療有效量之活性劑。然而,熟習此項技術者將知曉,醫藥組合物可包含超過一種治療有效量(即,散裝組合物)或少於一種治療有效量(即,設計用於多次投與以達成治療有效量之個別單位劑量)。 通常,醫藥組合物將包含約0.01至約95重量%之活性劑,包括約0.01至約30重量%,諸如約0.01至約10重量%,實際量係取決於調配物、投藥途徑、給藥頻率等。例如,適用為口服劑型之醫藥組合物可包含約0.1至約10重量%(包括約約0.5至約5重量%)之活性劑。 在一個代表性實施例中,醫藥組合物包含約0.5至約20 mg活性劑/單位劑量,包括約1至約10 mg活性劑/單位劑量。例如,該活性劑可調配成1、2、3、4、5、6、7、8、9或10 mg單位劑量,諸如1 mg、3 mg、5 mg及10 mg單位劑量。 任何習知或適宜之醫藥上可接受之載劑可用於本發明之醫藥組合物中。特定載劑或載劑之組合之選擇將取決於各種因素,諸如投藥模式、劑量、給藥頻率、活性劑釋放定時及類似。就此而言,用於特定投藥模式之適宜醫藥組合物之製備完全在熟習醫藥技術者知識範疇內,及用於該等組合物中之載劑可於市面購得。以進一步說明之方式,習知調配物及調配技術述於例如Remington:The Science and Practice of Pharmacy,第20版,Lippincott Williams & White,Baltimore,Maryland (2000);及H. C. Ansel等人,Pharmaceutical Dosage Forms and Drug Delivery Systems,第7版,Lippincott Williams & White,Baltimore,Maryland (1999)中。 醫藥上可接受之載劑之代表性實例包括(但不限於):糖,諸如乳糖、葡萄糖及蔗糖;澱粉,諸如玉米澱粉及馬鈴薯澱粉;纖維素,諸如微晶纖維素、及其衍生物,諸如羧甲基纖維素鈉、乙基纖維素及乙酸纖維素;粉狀黃蓍膠;麥芽;明膠;滑石;賦形劑,諸如可可脂及栓劑蠟;油,諸如花生油、棉籽油、紅花子油、麻油、橄欖油、玉米油及大豆油;二醇,諸如丙二醇;多元醇,諸如甘油、山梨糖醇、甘露醇及聚乙二醇;酯,諸如油酸乙酯及月桂酸乙酯;瓊脂;緩衝劑,諸如氫氧化鎂及氫氧化鋁;海藻酸;無熱原水;等滲鹽水;林格氏溶液(Ringer's solution);乙醇;磷酸鹽緩衝液;推進劑壓縮氣體,諸如氟氯碳化物及氫氟碳化物;及用於醫藥組合物中之其他非毒性相容性物質。 醫藥組合物通常係藉由將活性劑與醫藥上可接受之載劑及任何選用的成分徹底且均勻地混合或摻合來製備。所得的經均勻摻合之混合物可接著使用習知程序及設備成型或加載成錠劑、膠囊、丸劑、筒罐、卡管、小瓶、瓶、分配器及類似者。 在一個實施例中,該醫藥組合物係適合口服。用於口服之醫藥組合物可呈例如膠囊、錠劑、丸劑、含片、扁囊劑、糖衣藥丸、粉末、顆粒、溶液、懸浮液、乳液、酏劑、糖漿及類似之形式;各包含預定量之活性劑。 當計劃以固體劑型(諸如膠囊、錠劑及類似者)用於口服時,該醫藥組合物將通常包含活性劑及一或多種醫藥上可接受之固體載劑,諸如檸檬酸鈉或磷酸二鈣。固體劑型亦可包括:填料或增積劑,諸如澱粉、微晶纖維素、乳糖、蔗糖、葡萄糖、甘露糖及/或矽酸;黏合劑,諸如羧甲基纖維素、藻酸鹽、明膠、聚乙烯吡咯啶酮、蔗糖及/或阿拉伯膠;保濕劑,諸如甘油;崩解劑,諸如交聯羧甲纖維素鈉、瓊脂、碳酸鈣、馬鈴薯或樹薯澱粉、海藻酸、特定矽酸鹽及/或碳酸鈉;溶解阻滯劑,諸如石蠟;吸收加速劑,諸如四級銨化合物;潤濕劑,諸如十六烷醇及/或單硬脂酸甘油酯;吸附劑,諸如高嶺土及/或膨潤土;潤滑劑,諸如滑石、硬脂酸鈣、硬脂酸鎂、固體聚乙二醇、月桂基硫酸鈉及/或其混合物;著色劑;緩衝劑;釋放劑;包衣劑;甜味劑、矯味劑及芳香劑;及防腐劑及抗氧化劑。 用於錠劑、膠囊、丸劑及類似物之代表性包衣劑包括彼等用於腸溶性包衣者,諸如乙酸鄰苯二甲酸纖維素、乙酸鄰苯二甲酸聚乙烯酯、鄰苯二甲酸羥丙基甲基纖維素、甲基丙烯酸-甲基丙烯酸酯共聚物、乙酸偏苯三酸纖維素、羧甲基乙基纖維素、乙酸琥珀酸羥丙基甲基纖維素、聚乙烯醇及類似者。 代表性抗氧化劑包括:水溶性抗氧化劑,諸如抗壞血酸、半胱胺酸鹽酸鹽、硫酸氫鈉、偏亞硫酸氫鈉、亞硫酸鈉及類似者;油溶性抗氧化劑,諸如壞血酸棕櫚酸酯、丁基化羥基苯甲醚、丁基化羥基甲苯、卵磷脂、沒食子酸丙酯、α-生育酚及類似者;及金屬螯合劑,諸如檸檬酸、乙二胺四乙酸、山梨糖醇、酒石酸、磷酸及類似者。 醫藥組合物亦可使用例如不同比例之羥丙基甲基纖維素或其他聚合物基質、脂質體及/或微球體調配以緩慢或控制釋放活性劑。此外,該醫藥組合物可包含乳濁劑及可經調配使得彼等僅釋放活性劑,或優先地,在胃腸道之某一部分中,視需要,以延遲方式釋放。可使用的包埋組合物之實例包括聚合物質及蠟。活性劑亦可在適宜的情況下與上述賦形劑中之一或多者一起呈微型封裝形式。 用於口服之適宜液體劑型包括(例如)醫藥上可接受之乳液、微乳液、乳液、懸浮液、糖漿及酏劑。液體劑型通常包含活性劑及惰性稀釋劑,諸如,例如,水、汁或其他溶劑、增溶劑及乳化劑,諸如乙醇、異丙醇、碳酸乙酯、乙酸乙酯、苄醇、苯甲酸苄酯、丙二醇、1,3-丁二醇、油(例如,棉籽油、花生油、玉米油、胚芽油、橄欖油、蓖麻油及麻油)、甘油、四氫呋喃醇、聚乙二醇及山梨糖醇之脂肪酸酯、及其混合物。懸浮液可包含懸浮劑,諸如,例如乙氧基化異硬脂醇、聚氧乙烯山梨糖醇及山梨糖醇酐酯、微晶纖維素、偏氫氧化鋁、膨潤土、瓊脂-瓊脂及黃蓍膠、及其混合物。 在另一個實施例中,該醫藥組合物係適於局部投與,諸如經皮投與。就該投與而言,可使用已知的經皮傳遞系統及賦形劑。例如,可將活性劑與滲透增進劑,諸如丙二醇、聚乙二醇單月桂酸酯、氮雜環烷-2-酮及類似混合,且併入貼片或類似傳遞系統中。若需要,則其他賦形劑,包括膠凝劑、乳化劑及緩衝劑可用於該等經皮組合物中。 在另一個實施例中,該醫藥組合物係適合非經腸投與(例如,藉由皮下、靜脈內、肌肉內或腹膜內注射)。就該投與而言,活性劑係呈無菌溶液、懸浮液或乳液形式提供。用於製備該等調配物之例示性載劑包括水、鹽水、低分子量醇,諸如丙二醇、聚乙二醇、油、明膠、脂肪酸酯(諸如油酸乙酯)及類似者。非經腸調配物亦可包含一或多種增溶劑、穩定劑、防腐劑、潤濕劑、乳化劑及分散劑。該等調配物可藉由使用無菌可注射介質、殺菌劑、過濾、照射或熱變成無菌。 一種典型靜脈內調配物為包含活性劑及生理上可接受之水性載劑之無菌pH 4-7水溶液。代表性生理上可接受之水性載劑包括(例如)無菌注射用水,USP;葡萄糖注射液,USP(例如,2.5、5.0、10、20%葡萄糖,包括5%葡萄糖注射液(D5/W));葡萄糖及氯化鈉注射液,USP(例如,自2.5%至10%變化之葡萄糖及自0.12%(19 mEq鈉)至0.9%(154 mEq鈉)變化之氯化鈉);甘露醇注射液,USP(例如,5、10、15、20及25%甘露醇);林格氏注射液,USP(例如,147 mEq鈉、4 mEq鉀、4.5 mEq鈣及156 mEq氯離子/升);Lactated Ringer's注射液,USP(例如,2.7 mEq鈣、4 mEq鉀、130 mEq鈉及28 mEq乳酸鹽/升);氯化鈉注射液,USP(例如,0.9%氯化鈉)及類似者。當投與患者時,活性劑將通常係以約0.1 mL至約10 mL水性載劑/mg活性劑,諸如約0.5至約5 mL/mg活性劑進行稀釋。接著,該給藥溶液通常係藉由靜脈內輸注投與患者。 藉由說明,可依以下實例中所述製備代表性醫藥組合物。 A.硬明膠膠囊
將活性劑(5 g)、經噴霧乾燥之乳糖(485 g)及硬脂酸鎂(10 g)徹底摻合。然後,將所得組合物加載至硬明膠膠囊(每個膠囊500 mg組合物)中。各膠囊之每一適合口服之單位劑量提供5 mg活性劑。 B.硬明膠膠囊
將活性劑(2 g)與澱粉(98 g)、微晶纖維素(98 g)及硬脂酸鎂(2 g)徹底混合。然後,使該混合物通過No. 45網目U.S.篩且加載至硬明膠膠囊中(200 mg組合物/膠囊)。每一膠囊中每一適於口服之單位劑量提供2 mg活性劑。 C.軟明膠膠囊
將活性劑(5 g)與聚氧乙烯山梨糖醇單油酸酯(65 g)及澱粉粉末(335 g)徹底摻合。然後,將該混合物加載至軟明膠膠囊中(400 mg組合物/膠囊)。每一膠囊中每一適於口服之單位劑量提供5 mg活性劑。 D.軟明膠膠囊
將活性劑(1 g)與微晶纖維素(290 g)及硬脂酸鎂(9 g)徹底摻合。然後,將該混合物加載至軟明膠膠囊中(300 mg組合物/膠囊)。每一膠囊中每一適於口服之單位劑量提供1 mg活性劑。 E.錠劑
使活性劑(10 g)、澱粉(45 g)及微晶纖維素(35 g)通過No. 20網目U.S.篩且徹底混合。在50-60℃下乾燥所得顆粒且使其通過No. 16網目U.S.篩。分別地,將聚乙烯吡咯啶酮溶液(4 g,呈含在無菌水中之10%溶液形式)與羧甲基澱粉鈉(4.5 g)、硬脂酸鎂(0.5 g)及滑石(1 g)混合,及使該混合物通過No. 16網目U.S.篩。然後,將所得混合物添加至該等顆粒。在徹底混合之後,在壓錠機中將該混合物壓縮以形成分別重100 mg之錠劑。每一錠劑中每一適於口服之單位劑量提供10 mg活性劑。 F.錠劑
將活性劑(40 g)與微晶纖維素(445 g)、發煙二氧化矽(10 g)及硬脂酸(5 g)徹底混合。然後,在壓錠機中將該混合物壓縮以形成分別重100 mg之錠劑。每一錠劑中每一適於口服之單位劑量提供8 mg活性劑。 G.錠劑
將活性劑(10 g)與玉米澱粉(50 g)、交聯羧甲纖維素鈉(25 g)、乳糖(110 mg)及硬脂酸鎂(5 mg)徹底摻合。然後,在壓錠機中將該混合物壓縮以形成分別重200 mg之錠劑。每一錠劑中每一適於口服之單位劑量提供10 mg活性劑。 H.錠劑
將活性劑(10 g)與玉米澱粉(230 g)及明膠(50 g)水溶液徹底摻合。乾燥該混合物且研磨至細粉。然後,將微晶纖維素(100 g)及硬脂酸鎂(10 g)與明膠調配物混合,研磨及在壓錠機中將所得混合物壓縮以形成分別重200 mg之錠劑。每一錠劑中每一適於口服之單位劑量提供5 mg活性劑。 I.糖漿
將以下成分徹底混合直到所有固體成分溶解:
所得糖漿每10 mL的適合口服的糖漿包含5 mg活性劑。 J.無菌靜脈內注射溶液
將活性劑(5 mg)與0.4 M乙酸鈉緩衝液(2.0 mL)摻合。視需要使用0.5 N鹽酸水溶液或0.5 N氫氧化鈉水溶液將所得溶液之pH調整至pH 4,及然後,添加足量注射用水以提供20 mL之總體積。然後,使混合物通過無菌過濾器(0.22微米)過濾以提供適於靜脈內輸注投與之無菌溶液。共同投與及組合
若需要,4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶或其醫藥上可接受之鹽可與一或多種其他治療劑(「第二藥劑」)組合投與以治療nOH或其症狀。 可與4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶或其醫藥上可接受之鹽組合投與之代表性類別之治療劑包括(例如)α1
-腎上腺素能受體(α1
-腎上腺素受體)激動劑、α2
-腎上腺素能受體(α2
-腎上腺素受體)拮抗劑、腎上腺皮質類固醇、正腎上腺素前驅物、膽鹼酯酶抑制劑;或其組合。熟習此項技術者將明瞭術語「α1
-腎上腺素能受體激動劑」、「α2
-腎上腺素能受體拮抗劑」、「腎上腺皮質類固醇」、「正腎上腺素前驅物」及「膽鹼酯酶抑制劑」包括化合物之在投與患者之後具有特定活性之所有形式,諸如醫藥上可接受之鹽、溶劑合物、結晶形式、多形體、前藥及類似者。同樣地,術語「第二藥劑」包括第二藥劑之所有形式,諸如醫藥上可接受之鹽、溶劑合物、結晶形式、多形體、前藥及類似者。 α1
-腎上腺素能受體激動劑之代表性實例包括去糖米多君、依替福林(etilefrine)、間羥胺、米多君及類似者或在各情況下其醫藥上可接受之鹽。米多君為去糖米多君之前藥,其為α1
-腎上腺素能受體激動劑。在一個實施例中,第二藥劑為米多君或其醫藥上可接受之鹽,諸如米多君鹽酸鹽。 α2
-腎上腺素能受體拮抗劑之代表性實例包括育亨賓(yohimbine)及類似者、或其醫藥上可接受之鹽。 腎上腺皮質類固醇之代表性實例包括氟氫可的松、乙酸氟氫可的松及類似者或在各情況下其醫藥上可接受之鹽。乙酸氟氫可的松為氟氫可的松之前藥。在一個實施例中,第二藥劑為乙酸氟氫可的松。 正腎上腺素前驅物之代表性實例包括屈西多巴或其醫藥上可接受之鹽。在一個實施例中,該第二藥劑為屈西多巴。 膽鹼酯酶抑制劑之代表性實例包括吡斯的明或其醫藥上可接受之鹽。在一個實施例中,該第二藥劑為吡斯的明或其醫藥上可接受之鹽,諸如溴吡斯的明。 4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶或其醫藥上可接受之鹽及第二藥劑可經物理混合以形成包含兩種藥劑之組合物;或各藥劑可分開地投與患者,同時地或連續地。例如,將4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶或其醫藥上可接受之鹽可使用習知程序及設備與第二藥劑組合以形成包含4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶或其醫藥上可接受之鹽之藥劑與第二藥劑之組合。此外,該等藥劑可與醫藥上可接受之載劑組合以形成包含4-[2-(2,4,6-三氟苯氧基甲基)苯基]-哌啶或其醫藥上可接受之鹽、第二藥劑及醫藥上可接受之載劑之醫藥組合物。在該實施例中,通常,將組合物之該等組分混合或摻合以得到物理混合物。該物理混合物然後可藉由任何適宜投藥途徑,諸如口服、局部或非經腸投藥模式投與至患者。 或者,該等藥劑可在投與患者之前仍舊單獨及相异。在該實施例中,該等藥劑在投與之前並非物理混合在一起,而是同時地或在不同時間呈獨立組合物形式投與。該等組合物可進行獨立包裝或可以套組形式包裝在一起。當在不同時間投與時,該第二藥劑通常將在投與4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶或其醫藥上可接受之鹽後小於24小時(例如,在自開始投與至給藥後約24小時之任何時間範圍內)投與。此亦稱為連續投與。因此,例如,4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶或其醫藥上可接受之鹽可與第二藥劑使用兩種錠劑(例如,一種錠劑用於各活性劑)同時或連續地經口投與,其中連續包括在投與4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶或其醫藥上可接受之鹽之前或之後或在某些其他時間(例如,之前或之後一小時;或之前或之後三小時等)立刻投與。或者,該組合可藉由不同投藥途徑投與,例如,一者經口及另一者經局部或非經腸式。 當用於本發明中時,該第二藥劑係以治療有效量(即,以當與4-[2-(2,4,6-三氟苯氧基甲基)苯基]-哌啶或其醫藥上可接受之鹽共投與時產生治療有利效果的量)使用。例如,該等藥劑通常係以其已核准的劑量使用。例如,米多君鹽酸鹽通常係多達每天三次以在約2.5 mg至約10 mg範圍內的量經口投與;及屈西多巴通常係多達每天三次以在約100 mg至約600 mg範圍內的量經口投與。 用途 期望4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶可用於治療神經性起立性低血壓(nOH)及與nOH相關之症狀,諸如眩暈、頭痛或患者感覺快要漆黑。 4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶具有可使其特別適用於治療nOH之各種性質。例如,不同於阿托西汀,4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶之代謝係藉由多種CYP450酵素催化及因此,不希望罹患CYP2D6不良代謝型(PM)表型之個體中暴露顯著增加(Baldwin等人,「TD-9855, a Novel Norepinephrine and Serotonin Reuptake Inhibitor (NSRI), Demonstrates Significantly Reduced Dependence on CYP2D6 Metabolism Relative to Atomoxetine」 Poster Presented at American Association of Pharmaceutical Scientists Annual Meeting and Exposition,Poster No. W4278,San Antonio, TX (2013);摘要編號AAPS2013-000666)。更具體言之,4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶之代謝主要受CYP2D6化學抑制(減少7%)影響及主要藉由CYP3A4及CYP1A2介導(分別減少34%及25%)。相比之下,阿托西汀代謝主要受CYP2D6之化學抑制影響(減少94%)而未顯著受其他CYP450酵素之抑制影響。因此,相對阿托西汀而言,預期4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶具有顯著減小之藥物-藥物相互作用之可能性及減小之對與CYP2D6多態性相關聯之傾向之易感性。 在一個實施例中,4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶或其醫藥上可接受之鹽係用以治療由原發自主神經衰竭(包括單純性自主神經衰竭、多發性系統萎縮症及帕金森氏症)或自主神經萎縮症(包括糖尿病性及非糖尿病性自主神經萎縮症)引起的症狀性nOH。 在一個特定實施例中,4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶或其醫藥上可接受之鹽係用以治療由原發自主神經衰竭引起的症狀性nOH。在該實施例中,該患者可診斷患有單純性自主神經衰竭、多發性系統萎縮症及/或帕金森氏症。在一個實施例中,該患者具有單純性自主神經衰竭。在另一個實施例中,該患者具有多發性系統萎縮症。此外,在另一個實施例中,該患者具有帕金森氏症。 原發自主神經衰竭(亦稱為原發自主神經機能障礙)係一類自主神經機能障礙,即,自主神經系統未正確發揮作用之病症。在原發自主神經衰竭中,該自主神經功能障礙以與由另一疾病(諸如糖尿病)引起之第二病症相反之原發病症形式發生。例如,通常,當自主神經由特徵係自主神經系統退化之慢性病症引起時或在自主神經衰竭係主要症狀且其病因未知情況下,自主神經衰竭被歸類為「原發」。歸類為原發自主神經衰竭之病症包括單純性自主神經衰竭、多發性系統萎縮症及帕金森氏症。 單純性自主神經衰竭(PAF)(亦稱為Bradbury-Eggleston症候群或特發性起立性低血壓)係自主神經系統之退化性疾病。PAF之主要症狀為起立性低血壓。其他症狀可包括減少之出汗、怕熱、閉尿、膀胱痙攣(可能引起尿失禁)、勃起功能障礙、大便失禁或便秘、及瞳孔異常。PAF的病因尚未完全瞭解,但在罹患PAF之患者中已證實脊髓中外側柱中細胞之損失。此外,PAF可能與α-突觸核蛋白之異常積聚有關。 帕金森氏症(PD)為慢性進行性運動障礙。病因未知,但PD涉及中腦之稱為黑質之區域中神經元之功能障礙及死亡。該等神經元產生多巴胺,其在運動及協調上扮演關鍵角色。隨著PD發展,腦中之多巴胺產量減少,從而導致運動控制及協調問題。症狀包括震顫、僵硬、運動減慢及姿勢不穩定性。然而,一些PD患者亦經歷非運動症狀,包括因自主神經系統改變所致之起立性低血壓,即PD加上nOH之症狀。此外,一些具有PD症狀之患者具有稱為帕金森疊加症候群(或病症或多發性系統萎縮症)之病症。帕金森疊加症候群為一群產生PD之典型症狀(震顫、僵硬、失動症/運動遲緩、及姿勢不穩)及另外出現可與單純性特發性PD區分之其他特徵之神經退化性疾病。區分帕金森重疊症候群與特發性PD之臨床特徵包括症狀性發作、靜止性震顫無規律或缺乏、及對多巴胺性藥物(包括左多巴)反應之減小。其他特徵包括運動遲緩、早發性姿勢不穩、中軸肌僵硬之增加、自主神經異常、外星人肢症候群、核上凝視麻痺、失用症、小腦(包括椎體細胞)之侵犯及在一些情況下之顯著認知受損。 多發性系統萎縮症(MSA)(亦稱為Shy–Drager症候群)為特徵在於同時影響自主神經系統與運動之症狀組合之進行性神經退化性疾病。MSA之初始症狀通常很難與帕金森氏症之初始症狀區分,且包括動作減慢、震顫或僵化(僵硬);笨拙或不協調;語言能力受損、低沉沙啞、聲音顫抖;由於起立性低血壓引起之昏厥或頭痛;膀胱控制問題,諸如猝發撒尿或排空膀胱困難。MSA分成兩大類,取決於評估個體時之大多數顯著症狀:帕金森氏病類型(MSA-P),具有類似於帕金森氏症之主要特徵(諸如運動遲緩、僵硬及震顫)及平衡、協調問題及自主神經系統功能障礙;及小腦類型(MSA-C),具有特徵係共濟失調之主要症狀(平衡及協調問題)、吞咽困難、言語異常或聲音顫抖及眼球運動異常。MSA之病因未知。MSA之顯著特徵係蛋白質α-突觸核蛋白積聚於神經膠質中,該等神經膠質細胞支持腦神經細胞。α-突觸核蛋白之該等沉積尤其發生在寡樹突神經膠質瘤中,寡樹突神經膠質瘤係一種製造髓磷脂之細胞(塗佈在神經細胞上而使得彼等快速進行電信號傳遞)。最新研究指出α-突觸核蛋白之朊病毒形式可為該疾病之病因(Prusiner等人,PNAS,(2015) 112:E5308-17)。 由於MSA之藥理學的緣故,4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶或其醫藥上可接受之鹽尤其適用於治療MSA。更具體言之,MSA之特徵係中樞自主神經路徑變性;然而,在MSA患者中,周邊神經節後去甲腎上腺素能纖維及兒茶酚胺再吸收機制看起來完整,因此維持交感緊張(Biaggioni,Pharmacolgical Reviews (2017) 69(1):53-62)。通常,藉由正腎上腺素活化中樞α2-腎上腺素受體介導之CNS抗交感神經活性阻礙站立後周邊正腎上腺素濃度之增加,因此緩解周邊加壓效應及維持姿勢性正常血壓。然而,在MSA中,完整周邊交感神經節後腎上腺素能受體纖維基本上「中斷」CNS調節,從而使得正腎上腺素壓力效應完全無遮蔽。雖然該等患者中之殘餘交感緊張因該「中斷」而無法藉由壓力反射路徑或CNS輸入調節,但其可在藥理學上進行標靶。利用該獨特病理生理學,使用4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶或其醫藥上可接受之鹽增加周邊交感神經突觸正腎上腺素,將引起罹患nOH之MSA患者中壓力效應。因此,在一個特定實施例中,使用4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶或其醫藥上可接受之鹽以治療由MSA引起之症狀性nOH。 在另一個特定實施例中,4-[2-(2,4,6-三氟苯氧基甲基)苯基]-哌啶或其醫藥上可接受之鹽係用以治療由自主神經病變引起之症狀性nOH。自主神經病變(或自主神經機能障礙)係指自主神經系統(ANS)未正確地工作之各種病症。自主神經病變係一種影響神經之從腦及脊髓攜帶資訊至心臟、膀胱、腸、汗腺、瞳孔及血壓之神經病變。個體間可不同之自主神經病變之主要症狀包括:起立性低血壓;口乾;快速心率;隧道視力;吞咽困難;大便失禁;視力模糊;尿失禁;便秘;無汗症;及性功能障礙。自主神經病變可歸因於承襲或退化性神經疾病(原發性自主神經機能障礙)或其可由於自主神經系統因獲得性疾病(繼發性自主神經機能障礙)損傷而發生。 當用於治療nOH或nOH之症狀時,4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶或其醫藥上可接受之鹽通常係以在約0.5 mg至約20 mg/天範圍內的量;或視需要投與患者。在一個實施例中,投與患者的量在約1 mg至約10 mg/天範圍內。在另一個實施例中,投與患者的量在約3 mg至約10 mg/天範圍內。在單獨及相異之實施例中,投與患者的量為1、2、3、4、5、6、7、8、9或10 mg/天,包括1 mg、3 mg、5 mg或10 mg/天。投與患者的量、投藥途徑及投藥頻率通常由治療患者的醫師決定。 可藉由任何可接受之投藥途徑,包括(例如)口腔、局部(包括經皮)及非經腸(包括靜脈內)投藥模式,投與4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶或其醫藥上可接受之鹽至患者。 在一個實施例中,4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶或其醫藥上可接受之鹽係呈固體或液體劑型形式經口投與患者。在一個特定實施例中,投與患者之形式為固體劑型,包括錠劑或膠囊。在另一個特定實施例中,投與患者之形式為液體劑型,包括溶液、糖漿、懸浮液或乳液。 在另一個實施例中,投藥途徑係局部的。在一個特定實施例中,投藥途徑係經皮的,使用經皮貼片。 在另一個實施例中,投與途徑係非經腸式。在一個特定實施例中,投藥途徑係靜脈內投與。 4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶或其醫藥上可接受之鹽可單次日劑量(例如,每天一次);每天多個劑量(例如,每天兩次、三次或四次);或每週多個劑量(例如,每週兩次、三次或四次、五次或六次)投與患者。或者,可使用例如經皮貼片連續投與醫藥組合物。在一個特定實施例中,每天一次投與4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶或其醫藥上可接受之鹽至患者。實例
提供以下實例以說明本發明之各種代表性實施例及態樣而無意限制本發明之範疇,除非明確指明。 用於以下實例中之試劑、起始材料及溶劑係購自商業供應商(諸如Sigma-Aldrich、St. Louis, MO及其附屬公司)且無需進一步純化即可使用,除非另外指明。 除非另外指明,否則以下縮寫具有以下含義: AcOH 乙酸 BP 血壓 BSA 牛血清白蛋白 CHO 中國倉鼠卵巢 DA 多巴胺 DAT 多巴胺轉運體 DCM 二氯甲烷 DIPEA N,N-二異丙基乙胺 DMEM 杜貝卡氏改良之依格培養基(Dulbecco's Modified Eagle's Medium) DMF N,N-二甲基甲醯胺 DMSO 二甲亞碸 EDTA 乙二胺四乙酸 EtOAc 乙酸乙酯 EtOH 乙醇 FBS 胎牛血清 hDAT 人類多巴胺轉運體 HEPES 4-(2-羥乙基)-1-哌嗪乙磺酸 hNET 人類正腎上腺素轉運體 hSERT 人類血清素轉運體 5-HT 5-羥基色胺 IPA 異丙醇 IPAc 乙酸異丙酯 MeCN 乙腈 MeOH 甲醇 MSA 多發性系統萎縮症 NA 去甲腎上腺素 NE 正腎上腺素 NET 正腎上腺素轉運體 NF 國家處方書(National Formulary)級別 PAF 原發性自主神經衰竭 PBS 磷酸鹽緩衝鹽水 PD+ 帕金森氏症加上nOH之症狀 SBP 收縮壓 SERT 血清素轉運體 TFA 三氟乙酸 THF 四氫呋喃 Tris 三(羥甲基)胺基甲烷 用於本文中但未進行定義的其他縮寫具有其為具有其等所屬一般技術者所瞭解之一般含義。 除非另有說明,否則於400 MHz Varian AS400光譜分析儀上記錄1
H NMR光譜。化學位移表示為相對作為內標物的四甲基矽烷(TMS)的δ值,單位為ppm。耦合常數(J值)以赫茲(Hz)表示及多重性用以下縮寫表示:s=單重峰,d=雙重峰,t=三重峰,q=四重峰,m=多重峰,br=寬,nd=未測定。實例 1 4-(2- 羥甲基苯基 ) 哌啶 -1- 羧酸第三丁酯之製備
在室溫下,於氮氣下,將4-(2-羧基苯基)哌啶-1-羧酸第三丁酯(5.0 g,16 mmol,1.0當量)及THF(130 mL,1.7 mol)組合。滴加硼烷二甲亞碸複合物(2.9 mL,33 mmol,2.0當量)及攪拌該混合物5分鐘,然後,在回流下加熱1小時。使混合物冷卻至室溫及藉由滴加MeOH(40 mL)淬滅反應。然後,藉由旋轉蒸發濃縮該混合物及使所得材料與MeOH(2 x 40 mL)共沸。然後,用EtOAc(100 mL)稀釋該混合物,及用鹽酸水溶液(1 M;2 x 50 mL)洗滌,然後,用飽和碳酸氫鈉水溶液(2 x 50 mL)洗滌,接著用飽和氯化鈉水溶液(1 x 50 mL)洗滌。在無水硫酸鈉上乾燥有機層,過濾,然後在真空中濃縮以得到呈透明淺黃色油之在靜置後固化之4-(2-羥甲基苯基)-哌啶-1-羧酸第三丁酯(4.8 g)。1
H NMR (CDCl3
) δ (ppm) 7.34-7.22 (m, 3H); 7.19 (dt, J = 1.6 Hz, 7.2, 1H); 4.73 (s, 2H); 4.32-4.14 (m, 2H); 3.00 (tt, J = 4.0 Hz, 12.0, 1H); 2.80 (t, J = 11.6 Hz, 2H); 1.78-1.56 (m, 4H); 1.47 (m, 9H)。實例 2 4-[2-( 甲苯 -4- 磺醯氧基甲基 ) 苯基 ] 哌啶 -1- 羧酸第三丁酯之製備
將4-(2-羥甲基苯基)哌啶-1-羧酸第三丁酯(0.4 g,1.0 mmol,1.0當量)及三乙二胺(220 mg,2.0 mmol,1.4當量)溶解於DCM(11 mL,170 mmol)中。在0℃下,於氮氣下,使混合物冷卻,及添加對甲苯磺醯氯(290 mg,1.5 mmol,1.1當量)。在0℃下,攪拌所得混合物60分鐘。用EtOAc(50 mL)稀釋該混合物且用水(2 x 25 mL)洗滌。在無水硫酸鈉上乾燥有機層,過濾且藉由旋轉蒸發濃縮,以產生標題化合物(500 mg),其無需進一步純化即可使用。1
H NMR (CDCl3
) δ (ppm) 7.81 (t, J = 2.0 Hz, 1H); 7.79 (t, J = 2.0 Hz, 1H); 7.37-7.32 (m, 4H); 7.25-7.21 (m, 1H); 7.21-7.13 (m, 1H), 5.12 (s, 2H); 4.34-4.12 (m, 2H); 2.81-2.61 (m, 3H); 2.45 (s, 3H); 1.70-1.52 (m, 4H); 1.48 (s, 9H)。實例 3 4-[2-(2,4,6- 三氟苯氧基甲基 ) 苯基 ] 哌啶三氟乙酸鹽之製備
將4-[2-(甲苯-4-磺醯氧基甲基)苯基]哌啶-1-羧酸第三丁酯(2.1 g,4.7 mmol,1.0當量)溶解於MeCN(46 mL,890 mmol)中,且添加至碳酸鉀(1.9 g,14 mmol,3.0當量)及2,4,6-三氟苯酚(1.0 g,7.0 mmol,1.5當量)。在50℃下振蕩混合物過夜,然後,冷卻至室溫。將上清液與碳酸鉀及其他固體分離。將TFA(7 mL,90 mmol,20.0當量)添加至上清液及在室溫下振蕩該混合物過夜。然後,濃縮該溶液及將殘餘物溶解於1:1乙酸/水(5.0 mL)中。添加另一份乙酸(2.0 mL)及過濾該混合物且藉由製備性HPLC純化以得到標題化合物(1.3 g,97.5%純度)。MS m/z:C18
H18
F3
NO之[M+H]+
計算值,322.13;實測值322.2。1
H NMR (CDCl3
) δ (ppm) 9.83 (br.s, 1H); 9.32 (br.s, 1H); 7.46-7.39 (m, 2H); 7.32 (d, J = 6.8 Hz, 1H); 7.26-7.21 (m, 1H); 6.76-6.66 (m, 2H); 5.07 (s, 2H); 3.69-3.50 (m, 2H); 3.38 (t, J = 11.6 Hz, 1H); 3.20-3.02 (m, 2H); 2.19 (q, J = 12.8 Hz, 2H); 2.12-2.01 (m, 2H)。實例 4 4-(2- 羥甲基苯基 ) 哌啶 -1- 羧酸第三丁酯之製備
在室溫下,於氮氣下,將4-(2-羧基苯基)哌啶-1-羧酸第三丁酯(5.0 g,160 mmol,1.0當量)及THF(100 mL,1.0 mol)組合。歷時10分鐘滴加含在THF(1.0 M,32.7 mL,32.7 mmol,2.0當量)中之硼烷-THF錯合物(5℃溫升,放出氣體)。在室溫下攪拌反應混合物5分鐘,然後在50℃下加熱1小時。使該反應混合物冷卻至室溫及藉由慢慢地添加MeOH(30 mL)(溫和溫升,放出大量氣體)淬滅該反應。然後,藉由旋轉蒸發濃縮該混合物。使所得材料與MeOH(2 x 50 mL)共沸。將粗產物溶解於EtOAc(100 mL)中及用飽和碳酸氫鈉水溶液(50 mL)洗滌及然後用飽和氯化鈉溶液(50 mL)洗滌。在無水硫酸鈉上乾燥有機層,過濾,及在真空中濃縮以得到呈透明淺黃色油之在靜置後固體之4-(2-羥甲基苯基)哌啶-1-羧酸第三丁酯(4.4 g)。實例 5 4-(2- 甲烷磺醯氧基甲基苯基 ) 哌啶 -1- 羧酸第三丁酯之製備
將4-(2-羥甲基苯基)哌啶-1-羧酸第三丁酯(50.0 g,172 mmol,1.0當量)溶解於DCM(500 mL,8000 mmol)中。在0℃下,於氮氣下,使混合物冷卻,且一次性添加甲磺酸酐(44.8 g,257 mmol,1.5當量)。歷時5分鐘滴加二異丙基乙胺(47.8 mL,274 mmol,1.6當量)且在0℃下攪拌該混合物90分鐘。添加水(400 mL,20 mol)並攪拌該混合物5分鐘。分離各相,及用水(300 mL)洗滌有機層,於無水硫酸鈉上乾燥,及移除溶劑以得到呈黏稠油之標題化合物(70 g),其無需進一步純化即可使用。1
H NMR (400 MHz, DMSO-d6
) δ (ppm) 7.37-7.43 (m, 3H), 7.31 (d, 1H), 7.22 (m, 2H), 5.38 (s, 2H), 4.28 (m, 2H), 2.92-3.10 (m, 1H), 2.92 (s, 3H), 2.80-2.92 (m, 2H), 1.63-1.81 (m, 4H), 1.51 (s, 9H)。實例 6 4-[2-(2,4,6- 三氟苯氧基甲基 ) 苯基 ] 哌啶 -1- 羧酸第三丁酯之製備
將4-(2-甲烷磺醯氧基甲基苯基)哌啶-1-羧酸第三丁酯(27.0 g,60.6 mmol,1.0當量)溶解於MeCN(540 mL)中且添加至碳酸鉀(25 g,180 mmol,3.0當量)及2,4,6-三氟苯酚(13.5 g,90.9 mmol,1.5當量)。在50℃下強力攪拌該混合物6小時,移除熱量,及攪拌過夜。使該混合物在室溫下冷卻及用EtOAc(700 mL)及水(700 mL)稀釋。分離各相及用氫氧化鈉水溶液(1.0 M;2 x 400 mL)及飽和氯化鈉水溶液(1 x 400 mL)洗滌有機層,及然後,在無水硫酸鈉上乾燥。然後,移除溶劑以得到粗4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶-1-羧酸第三丁酯(25.0 g)。將該粗產物與小規模實驗組合總共得到30 g及藉由層析(0‑10% EtOAc/己烷)純化以得到4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶-1-羧酸第三丁酯(22.0 g)。實例 7 4-[2-(2,4,6- 三氟苯氧基甲基 ) 苯基 ] 哌啶鹽酸鹽之製備
將4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶-1-羧酸第三丁酯(22.0 g,31.3 mmol,1.0當量)與含在EtOH(250 mL,310 mmol,10.0當量)中之1.25 M HCl組合。在室溫下攪拌混合物8小時,然後,在-10℃下儲藏約48小時。藉由旋轉蒸發移除大多數溶劑。將EtOAc(80 mL)添加至所得黏稠漿液,接著,在室溫下攪拌2小時。藉由過濾單離第一批晶體,及用EtOAc(20 mL)洗滌濾餅並乾燥以得到呈白色固體之標題化合物(8.5 g,>99%純度)。濾液之HPLC顯示~25%面積之產物。就第二批而言,藉由旋轉蒸發移除溶劑及在EtOAc(40 mL)中,先在室溫下,接著在60℃,及再在室溫下漿化所得固體(~10 g)以得到呈鹽酸鹽形式之標題化合物(1.7 g,>99%純度)。 將兩批鹽酸鹽(18.5 g,51.7 mmol)與EtOAc(75 mL,770 mmol)組合。在65℃下加熱所得的黏稠但自由流動之漿液30分鐘,冷卻至室溫,然後,過濾。用EtOAc(20 mL)洗滌燒瓶及濾餅,及在室溫下,於高真空下乾燥固體過夜,以得到鹽酸鹽結晶(18.2 g,99.3%純度)。實例 8 4-[2-(2,4,6- 三氟苯氧基甲基 ) 苯基 ] 哌啶鹽酸鹽之製備
將乙醯氯(83.5 mL,1170 mmol)慢慢地添加至EtOH(140 mL,2.4 mol)。添加已溶於EtOH(100 mL,2.0 mol)中之4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶-1-羧酸第三丁酯(55.0 g,117 mmol)且在室溫下攪拌所得混合物6小時。藉由旋轉蒸發移除大多數溶劑。將EtOAc(300 mL)添加至所得黏稠漿液,接著,移除部分溶劑至~100 mL。添加EtOAc(200 mL)及攪拌所得漿液1小時,過濾並乾燥以得到標題化合物(28.0 g,~99%純度)。濃縮濾液至黏稠糊劑及添加IPAc(100 mL),攪拌1小時,過濾並乾燥以進一步得到5.0 g鹽酸鹽(~99%純度)。 將兩批鹽酸鹽(83.0 g,230 mmol,~99%純度)與EtOAc(250 mL,2.6 mol)組合。在70℃下加熱所得漿液及然後慢慢地冷卻至室溫,接著,攪拌過夜。過濾所得自由流動漿液及用EtOAc(50 mL)洗滌濾餅,然後在高真空下乾燥約48小時以得到鹽酸鹽結晶(81.0 g,>99%純度)。 將鹽酸鹽結晶(50.0 g,1.40 mol,>99%純度)溶解於IPA(250 mL,3.3 mol)中,及加熱所得漿液至75℃。添加水(25 mL,1.4 mol)。在5分鐘內觀察到完全溶解,及溶液內部溫度為65℃。使該溶液慢慢地冷卻至室溫及然後在室溫下攪拌過夜。過濾所得固體及在空氣下乾燥2小時以得到半乾產物。然後,在高真空下,於室溫下,乾燥固體約48小時以得到標題鹽酸鹽結晶(44.1 g,99.5%純度)。將該物質用於實例9及10中所述的PXRD及DSC分析法中。實例 9 粉末 X 射線繞射
利用Rigaku Miniflex PXRD繞射儀,使用Cu Kα(30.0 kV,15.0 mA)輻射,獲得粉末X射線繞射圖案。利用測角器運行,依連續掃描模式每分鐘2°(2θ),步長0.03°,在2°至40°之2-θ角範圍內,進行分析。在石英樣品固定架上製備呈粉狀材料薄層之樣品。用矽金屬標準物,於±0.02°2-θ角內校準儀器。在測試之前手工研磨該等樣品,以減小粒徑對相對強度之干擾。實例8之鹽酸鹽結晶之代表性PXRD圖案顯示於美國專利第8,304,433 B2號之圖1中。PXRD峰按照相對強度遞減的順序顯示於表1中。藉由每個峰減去對應背景強度來收集所有PXRD峰強度。表 1 粉末 X 射線繞射數據
在一個實施例中,用於本發明中之鹽酸鹽結晶之特徵在於特徵係在4.44±0.20、10.22±0.20、17.16±0.20及21.78±0.20之2θ值處包含繞射峰之粉末x射線。在另一個實施例中,鹽酸鹽結晶之另一特徵係在選自8.11±0.20、13.18±0.20、16.06±0.20、18.38±0.20、23.76±0.20、26.32±0.20、27.24±0.20、29.60±0.20及31.94±0.20之2θ值處具有一或多個其他繞射峰。實例 10 差示掃描量熱法
使用具有熱分析控制器之TA儀器模型Q-100模組進行差示掃描量熱法(DSC)。收集數據並使用TA儀器熱溶液軟體分析。準確地稱取實例8之鹽酸鹽結晶之2.8 mg樣品至加蓋鋁盤中。在22℃之5分鐘等溫平衡期之後,利用10℃/min之線性加熱斜升率,將樣本從22℃加熱至250℃。代表性DSC熱譜圖顯示於美國專利第8,304,433 B2號之圖2中。DSC熱譜圖證實鹽酸鹽結晶具有熔點約196.9℃之較佳熱穩定性。 在一個實施例中,用於本發明中之鹽酸鹽結晶之特徵係具有約197±2℃熔點之差示掃描量熱法跡線。實例 11 放射性配體結合及神經傳遞質吸收檢定
4-[2-(2,4,6-三氟苯氧基甲基)苯基]-哌啶在人類重組及大鼠自然單胺轉運體下之活體外藥理學係如Smith等人,Inter. J. Neuropsychopharmcol. (2015) 1-11;及Tsuruda等人,J. Pharmacol. Toxicol. Meth. (2010) 61:192-204中表徵。亦參見,例如,美國專利第8,304,432 B2號及第8,304,433 B2號。放射性配體係自商業上購得(Perkin Elmer LifeSciences或GE Healthcare Life Sciences)。 簡言之,在22℃下,在不存在或存在含在50 mM Tris-HCl、120 mM NaCl、5 mM KCl、0.025% BSA、100 μM抗壞血酸,pH 7.4中之4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶及就SERT而言[3
H]-西酞普蘭(citalopram)(1.0 nM)、就NET而言[3
H]-尼索西汀(nisoxetine)(2.0 nM)及就DAT而言[3
H]-WIN35428(3.0 nM)下,培養自經人類重組SERT (HEK293-hSERT)、NET(HEK293-hNET)或DAT(CHO-K1-hDAT)穩定轉染之HEK293(人類胚胎腎臟293)或CHO-K1(中國倉鼠卵巢-K1)細胞製備之膜1小時。在22℃下,用就SERT而言[3
H]-西酞普蘭(2.0 nM)或就NET而言[3
H]-尼索西汀(4.0 nM)培養將大鼠皮質膜製劑1小時。在神經傳遞質吸收檢定中,在37℃下,在不存在或存在含在7.5 mM HEPES、12.5 mM Tris–HCl、2.2 mM Na-磷酸鹽、120 mM NaCl、5 mM KCl、0.4 mM MgCl2
、7.5 mM葡萄糖、1.7 mM CaCl2
、250 μM抗壞血酸、150 μM帕吉林(pargyline)、0.025% BSA,pH 7.4中之4-[2-(2,4,6-三氟苯氧基甲基)苯基]-哌啶下,分別預培養HEK293-hSERT、hNET或hDAT細胞30分鐘,接著用[3
H]-5-HT (20 nM)、[3
H]-NE (40 nM)或[3
H]-DA (100 nM)培養10分鐘。將大鼠皮質突觸體與[3
H]-5-HT或[3
H]-NE培養6分鐘及將紋狀體突觸體與[3
H]-DA培養6分鐘。藉由快速過濾終止結合及吸收檢定及藉由液體閃爍光譜進行放射活性之確定。最終[3
H]-神經傳遞質濃度明顯低於各自的Km
,因此pIC50
約為功能性pKi
。如下確定NET之選擇性(四捨五入至一位重要數字): 選擇性=10( 在 NET 下之 pKi 或 pIC50 減去在 SERT 或 DAT 下之 pKi 或 pIC50)
。 4-[2-(2,4,6-三氟苯氧基甲基)-苯基]哌啶在人類及嚙齒動物單胺轉運體下之活體外藥理學性質相似,如表2中所顯示。表 2 在人類重組及大鼠天然 SERT 、 NET 及 DAT 轉運體下之活體外藥理學
數據表示為平均pIC50
(負以十為底的對數IC50
)及pKi
(負以十為底的對數Ki
)值。數據表示3至9個個別實驗之平均值(圓括號內為95%置信區間)。N.D.=未測定。 表2中之數據證實4-[2-(2,4,6-三氟苯氧基甲基)苯基]-哌啶為NET及SERT之有效抑制劑,但非DAT之有效抑制劑,對NET之抑制效力係4倍高於SERT。類似地,4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶為[3
H]-NE及[3
H]-5-HT之吸收至大鼠皮質突觸體中之有效抑制劑,NET之表觀功能選擇性(10-倍)優於SERT,類似於在人類轉運體處所觀察。與功能性抑制研究一致,4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶展現結合至人類NET及SERT(但不結合至DAT)之高親和力(表2)。大鼠皮質製備之膜中大鼠-自然NET及SERT之表觀結合親和力值相似於(重疊置信區間)對應之在人類轉運體處之值,與種類依賴性之缺乏相一致(表2)。實例 12 間接活體內轉運體佔用研究
在控制實驗室條件(在21±1℃下之溫度)下,基於12:12小時明暗循環,圈養成年雄性Sprague Dawley大鼠(Charles River)。在到達設施後,讓動物自由獲得食物及水,及使動物適應其起居室至少48小時。使動物空腹但在給藥之前允許自由獲取水15–18小時。 大鼠(n=6隻/時間點/劑量濃度)接受單一口服劑量之4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶(0.3、1、5、10、30及60 mg/kg)且在投藥後藉由斷頭法在指定時間點(0.5、2、4、6及8小時時,5 mg/kg劑量濃度;2小時時,0.3、1、10、30及60 mg/kg劑量濃度)將其安樂死。切下脊髓以用於間接活體內轉運體佔用及自相同動物進行PK評估。藉由液壓擠出,使用磷酸鹽緩衝鹽水,收穫脊髓,及切下腰部並在乾冰上冷凍。收集殘餘脊髓片段及在水(25% w/w)中均質化以用於PK分析。將所有樣品儲存於-80℃直到分析。 使用動力學放射性配體結合檢定以確定大鼠脊髓中之NET及SERT佔用,如前面在Bourdet等人,J. Pharm. Exp. Ther. (2012) 341:137-145中所述。藉由區室化模型化方法(WinNonlin第5.0.1版,Pharsight Corporation)估計PK/PD參數。評估具有一階吸收及消除之一-及二區室PK模型。選擇一區室模型。藥效動力學模型為直接連接至中央PK腔室(WinNonlin PK模型3、PD型101)之有效腔室Emax
模型。模型之選擇係使用Gauss-Newton最小方法基於在就視覺檢測、Akaike資訊標準及殘餘平方和方面進行最佳匹配。估計以下參數: k01 (hr-1
): 一階吸收率常數: V/F (L/kg): 依口服生物可利用性劃分的中央房室的體積 k10 (hr-1
): 中央房室之消除率常數 Emax
(佔用%): 在脊髓中之最大SERT或NET佔有率 EC50
(ng/mL): 與50% SERT或NET佔用相關之血漿4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶濃度 keo
(hr-1
): 中央藥物動力學腔室與藥效動力學效應腔室間的一階平衡速率常數 就NET及SERT佔用而言,源自效應腔室PK/PD分析之PK及PD參數估計顯示於表3中。表 3 大鼠脊髓中 4-[2-(2,4,6- 三氟苯氧基甲基 ) 苯基 ] 哌啶正腎上腺素及血清素轉運體佔用之藥物動力學及藥效動力學參數估計
最終參數估值以變異係數(CV%)列於提供於圓括號中之各參數估值。 如表3中所顯示,就NET而言,估計的佔用EC50
為11.7 ng/mL及就SERT而言,在大鼠脊髓中,為50.8 ng/mL。由於物種血漿蛋白結合差異(在大鼠及人類中,分別為90.2%及79.1%),工程化人類血漿EC50
值就NET而言為5.5 ng/mL及就SERT而言,為23.9 ng/mL。實例 13 在經麻醉大鼠中之心血管模型
進行該等研究以評估單一投與4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶於經麻醉大鼠之心率(HR)及平均動脈血壓(MAP)之效用。使用該心血管模型,對HR之內在影響及酪胺壓力反應之抑制評估為反映4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶抑制周邊正腎上腺素轉運體能力之替代物指標測量。A. 實驗設計
藉由腹膜內注射(IP)硫仲丁比妥鈉(Inactin)來麻醉體重在250 – 350 g之間的正常血壓雄性Sprague-Dawley大鼠。使所有動物保持在完全麻醉(即,對捏腳趾測試無反應)下以進行手術及持續進行實驗。單離右頸總動脈及頸靜脈並導管檢查。插進氣管以保持氣道在研究期間開放。在完成手術之後,將動脈導管連接至壓力傳感器及使用Notocord-HEM數據擷取系統記錄基線血壓[收縮壓(SBP)、平均動脈壓(MAP)及舒張壓(DBP)]及心率(HR)。在至少60分鐘之基線(即,最後10分鐘係穩定的)之後,投與媒劑(10% Tween20,2 mL/kg,IP)及監測任何可能之效應至少10分鐘。此後,對大鼠注射媒劑或4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶(0.01 – 30 mg/mL,2mL/kg,IP)及監測MAP及HR之變化25分鐘。然後,藉由頸靜脈插管靜脈內攻擊大鼠,以5分鐘時間間隔提供非累積單次劑量之酪胺(0.03、0.1、0.3及1 mg/kg、1 mL/kg,IV)。在最後一次給予酪胺之後,在實驗結束之前再繼續獲取數據10分鐘。在一個獨立組動物中,在給藥後15分鐘及60分鐘,採集血液以評估血漿中4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶之濃度。自15分鐘時所獲得的游離血漿濃度用於構成MAP及HR之濃度反應曲線(CRC),而自60分鐘時之濃度用於酪胺CRC。藉由二氧化碳窒息將動物安樂死,接著開胸。B. 數據分析
內在血液動力學效應表示為在酪胺攻毒之前由4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶引起之MAP或HR之最大變化。在媒劑對照組中,將酪胺效應之抑制與反應標準化至1 mg/kg劑量酪胺。使用Prism 5.00TM(GraphPad, Inc.)通過迭代曲線擬合至邏輯方程式來分析MAP、HR之變化及酪胺反應之抑制之濃度反應曲線(CRC)。使用的方程式如下: Y = (底部+頂部-底部)/(1+10^((LogEC50-X)*HillSlope)) 其中X為劑量之對數,Y為反應,Y始於底部(均受限於0)及以乙狀結腸形狀到達頂部。當MAP或HR之變化在高劑量下減小時,藉由在較低劑量下發生的最大效應遞延至所有隨後的較高劑量來達成頂部(即,最大效力)之更準確的估計。就酪胺CRC而言,TOP受限於100。壓力效應之效力表示為MAP PC10
,其為產生10 mm Hg之MAP變化之游離血漿濃度及HR效應之效力表示為HR PC25
,其為產生25 bpm之HR變化之游離血漿濃度。最後,抑制酪胺效應之效力表示為Tyr EC50
,其為對酪胺引起(1 mg/kg,IV)之SBP之增加產生50%抑制之濃度。 使用下式,將藉由測定大鼠皮質突觸體中大鼠血清素轉運體(rSERT)對經標記5-HT吸收之抑制得到的抑制效力(pIC50
值)轉化為IC50
值: Y=(10^(-x))x(10^9)C. 結果
4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶(0.01 – 30 mg/kg,IP)劑量獨立地增加經麻醉大鼠中之MAP及HR。當每種劑量相對於對應游離血漿濃度作圖時,估計的MAP及HR效力為101.4 nM (MAP EC10
)及8.6 nM (HR EC25
)。MAP及HR之最大變化分別為13.2 (4.4 – 22.1) mm Hg及28.1 (22.4-33.7) bpm。4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶亦抑制酪胺引起之SBP之增加。當表示為對1 mg/kg經靜脈內投與之酪胺反應之抑制%時,4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶之效力估算值為0.86 nM。D. 結論
在經麻醉大鼠之心血管模型中,4-[2-(2,4,6-三氟苯氧基甲基)-苯基]哌啶展現對酪胺壓力反應之有效抑制及心率過速與周邊NET之抑制一致。實例 14 口服溶液之製備
以兩個步驟製備口服4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶鹽酸鹽溶液。首先,製備3 mg/mL水性原液,及然後,在給藥前製備含在經過濾蘋果汁中之具有不同劑量強度之口服溶液。A. 原液之製備
將4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶鹽酸鹽(500 mg,89.9%純度)添加至250 mL透明玻璃瓶。添加無菌注射用水(150 mL)及將該瓶加蓋。以圓周運動輕輕地漩渦該瓶,直到觀察不到固體物質(約20分鐘)。若需要,亦可音波處理該瓶。標記該瓶及在2小時內使用原液(3 mg/mL)或於2-8℃下將其儲藏於冰箱中直至使用。丟棄從開始製備算6天內未使用的任何原液。B. 口服溶液之製備
製備具有七種不同劑量強度之口服溶液以用於臨床研究之部分A或部分B中。所製備的劑量強度及用於製備各劑量強度的量顯示於表4及5中:表 4 口服溶液 ( 部分 A) 表 5 口服溶液 ( 部分 B)
為製備口服溶液,從冰箱拿出原液(3 mg/mL)且目測檢查任何沉澱。若存在沉澱,則再製原液。 將蘋果汁(至少40 mL,Mott’s 100%初始蘋果汁)抽至50 mL針筒中及將針筒過濾器(25 mm PVDF針筒過濾器,0.2 µm,Pall Life Sciences)附接至針筒。通過針筒過濾器過濾蘋果汁,丟棄前3 mL及將其餘蘋果汁收集於125 mL琥珀色瓶中。 然後,將顯示於表4或5中之原液(3 mg/mL)之量(原液體劑)添加至新的125 mL琥珀色瓶及將顯示於表4或5中之對應量之經過濾之蘋果汁(蘋果汁體積)添加至該瓶。蓋住該瓶及藉由以圓週運動迴旋超過2分鐘將內含物混合。在投與患者之前,將所得溶液儲藏在環境室溫下至多18小時。在投與患者之前,將10 mL等分試樣之口服溶液轉移至新的125 mL琥珀色瓶中。實例 15 口服錠劑之製備
將微晶纖維素(4.476 kg;AVICEL微晶纖維素,NF,Ph.Eur Type PH-112)及無水乳糖(2.450 kg;無水60M NF,EP)加載至摻合箱(blending bin)中且在20 rpm下摻合5分鐘。將所得混合物轉移至雙重PE襯底容器(「預混物1」)中且分離成兩部分,一部分重約1 kg(「預混物1A」)及另一部分包含其餘物質(「預混物1B」)。將約一半的預混物1A添加至該箱,接著添加4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶鹽酸鹽(38.93 g;經研磨),及然後,添加另一半預混物1A。在20 rpm下摻合所得混合物10分鐘及然後轉移至雙重PE襯底容器(「預混物2」)中。在1000 rpm(800-1200 rpm)下,使約一半的預混物1B通過配備1.0 mm篩之研磨機,向前衝擊,接著係活性預混物2及然後係另一半預混物1B。將經研磨物質收集至雙重PE襯底容器(「經研磨之預混物3」)中。使經研磨預混物3通過40-網目手工篩,及將過篩材料轉移至摻合箱中並在20 rpm下摻合10分鐘(「活性摻合」)。移除一滿勺活性摻合物且人工將其與硬脂酸鎂(35.0 g, NF)在聚乙烯袋中混合。然後,使該混合物通過40網目手工篩。然後,將過篩混合物加回至摻合箱中且在20 rpm下摻合全部混合物5分鐘(「最終摻合物」)。使用壓錠機將最終摻合物壓縮成200 mg錠劑且使該等錠劑通過除塵器及金屬檢測器。將可接受之錠劑收集至雙重PE襯墊容器中。 將純水(1.587 kg,USP)添加至清潔不鏽鋼溶液製劑小瓶中且調整混合器速度以形成渦流。將基於聚乙烯醇之塗膜劑(280.0 g;OPADRY II Pink 85G64744,Colorcon, Inc.,West Point,PA)添加至混合槽中之渦流中及減小混合速度以致不再出現渦流且繼續混合至少45分鐘或直到目測觀察到顏色均勻分散。在塗佈製程之前及期間維持溫和之混合。將上文製得的錠劑加載至塗佈盤中且將盤速度設為10 rpm。將塗佈溶液抽汲至塗佈盤中。將其抽汲至塗佈盤中時監測塗佈溶液重量變化及當基於塗佈懸浮液用途再次達成4%錠劑乾重時,停止塗佈溶液之添加。所得粉色錠劑包含約1 mg 4-[2-(2,4,6-三氟苯氧基甲基)-苯基]哌啶(游離鹼當量)。 亦使用類似程序及以下量之材料:微晶纖維素(4.320 kg);無水乳糖(2.450 kg);4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶鹽酸鹽(194.7 g);硬脂酸鎂(35.0 g);純水(1.587 kg);以聚乙烯醇為主之塗膜劑(280.0 g;OPADRY II Yellow 85G620027),製備包含約5 mg 4-[2-(2,4,6-三氟苯氧基甲基)-苯基]哌啶(游離鹼當量)之黃色錠劑。實例 16 在具有 nOH 之個體中之臨床研究
用4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶鹽酸鹽(「研究化合物」)進行2期臨床試驗研究。該研究為罹患nOH之個體中研究化合物對安慰劑之多中心、隨機、兩部分、單盲(部分A)及雙盲(部分B)研究。亦將進行研究化合物之開放標示、延伸研究以評估效力、安全性及耐受性(部分C)。部分A遵循在第1天以安慰劑開始之每日、單一、遞增劑量設計,接著在第2天投與1 mg劑量的研究化合物,及每天繼續進行以遞增更高劑量之研究化合物直至10 mg之最大劑量,基於安全性、耐受性及加壓效應之測定判定。部分B遵循評估確定部分A中指定個體一般具良好耐受性且具有加壓效應之劑量之隨機、安慰劑對照、平行設計。部分C為評估歷時20週每天一次投與之研究化合物在證實係部分A中之反應者之個體中之效力(慢性加壓反應、nOH之症狀)、安全性及耐受性之開放標示、延伸研究。 包含於研究中之個體為已診斷因單純性自主神經衰竭、多發性系統萎縮症或帕金森氏症(例如,PD加上症狀)罹患症狀性起立性低血壓之40歲至80歲(含)之間的男性或女性。在篩選下,進行自主神經功能測試以證實自主神經功能障礙(包括竇性心律不齊及瓦氏動作(Valsalva maneuver))之診斷。個體必需:(1)在站立5分鐘內證實SBP≥30 mm Hg下降;(2)證實在瓦氏動作階段IV期間受損之自主神經反射,如藉由無BP過度確定;(3)站立時經歷眩暈、頭暈或暈厥;及(4)無其他可識別之自主神經病變病因。A. 劑量遞增研究 ( 部分 A)
在部分A中,依單盲方式(即,個體仍舊盲目),使用口服溶液,投與所有劑量(研究化合物及安慰劑)。至多30位個體入選部分A。在開始部分A前兩天,允許個體到臨床研究中心(CRC),其中彼等在整個劑量遞增期間留於此。第1天,個體接受單一劑量之安慰劑。第2天,個體接受1 mg單劑量之研究化合物。在之後的每一天,如下,個體接受單一遞增劑量之研究化合物:第3天,2.5 mg;第4天,5 mg;第5天,10 mg,除非出現以下預設停止標準: (a) 由研究者(與委託者合作)確定投與隨後的下一個劑量可能具有安全問題; (b) 在一小時內再重複2次坐姿狀態下,SBP ≥ 180 mm或DBP ≥ 110 mm; (c) 無法忍受之副作用,由研究者確定;或 (d) 個體接受最大劑量之方案所指定研究藥物。 一旦個體滿足任何上述標準,不再進行劑量遞增。於診所給藥後觀察時間,自CRC放出個體。 未證實基於研究者決定(與委託者合作)之SBP之臨床上有意義增加的個體或在達到停止標準之前停止研究藥物的個體不繼續進行研究部分B。個體無需完成所有四個研究化合物劑量以繼續進入研究部分B。接受至少一種使得坐式BP有效增加之研究化合物劑量且被視為大體上具良好耐受性之所有個體入選參與研究部分B及/或部分C。B. 清除期
於完成部分A之後,個體經歷清除期(最短8天,不超過36天)。每日前72小時排空,及接著在清除期其餘時間至少每週排空,研究者或設計人員經電話與個體聯繫以觀察個體健康狀態。藉由電話記錄任何不良事件及依醫學上合適的情況,由研究者確定進行。在研究者之指示下,個體在清除期間,使用所開立的其他藥物管理其nOH症狀。C. 隨機、雙盲、平行設計研究 ( 部分 B)
在清除期之後,個體可在開始部分B前兩天返回至CRC且隨機接受單一劑量之安慰劑或研究化合物。部分B中之治療分配係雙盲的,藉由指定非盲藥劑師在CRC處製備呈口服溶液之研究化合物。在部分B中,在研究者與委託者之間的協作下,個體接受達成相對在部分A期間確定的劑量的可比擬峰暴露以產生坐式BP之有效增加且被視為大體上具良好耐受性之研究化合物劑量。使用藥物動力學模型化來確定選擇用於部分B之個別化劑量以達成對應於部分A中如表6中所顯示投與之最終劑量之研究化合物之可比擬暴露。表 6 用於部分 B 之劑量確定 D. 開放標示、延伸研究 ( 部分 C)
就部分C而言,研究化合物係呈包裝成開放標記40-計數高密度聚乙烯瓶的1 mg或5 mg錠劑提供。在第1天,患者接受等於在部分A期間具耐受性之最高劑量之劑量。在第2天及此後,患者接受等於在部分C第1天投與之50%劑量(四捨五入至最小1 mg)之劑量。例如,若部分A中之最高劑量為10 mg/天,則在第1天,患者接受10 mg及在第2天及此後,患者接受5 mg/天。同樣地,若部分A中之最高劑量為5 mg/天,則在部分C之第1天,患者接受5 mg及在第2天及此後,患者接受3 mg/天。若患者發展成出現先前觀察到的仰位高血壓(SBP ≥ 180 mm Hg或DBP ≥ 110 mm Hg)或表明難受之其他不良事件出現或惡化,則該劑量保留3天且先前劑量濃度之劑量濃度50%(四捨五入至最小1 mg)再開始。若仰位高血壓或其他不良事件在已減小劑量之後持續,停止對該患者之給藥及對患者提供適宜之替代療法及照護,有主要研究者決定。或者,若劑量減小發生但患者在家,則在劑量減少的2週內將患者帶去門診。E. 研究評估
1.藥效評估
坐式及站式收縮壓及起立性低血壓症狀評估(OHSA)問卷之完成係用於評估效力。就部分C而言,若可用,則使用步行血壓監測以在血壓第1天給藥之前,歷時24小時每2小時;及在第15天、第29天、第85天及第169天臨床隨訪之前第72小時至第48小時進行測定。另外,每天清晨,飲食前20-30分鐘,約仰臥(抬高30°)至少10分鐘,測量血壓。 2.安全性評估
使用不良事件、臨床實驗室測試(包括血液學、血清化學及尿分析)、生命特徵、12-鉛ECG、合併用藥之使用及身體檢查以評估安全性。 3.藥物動力學 (PK) 評估
在部分A中,在給藥前(在給藥前30分鐘內及在評估站立BP及起立性評估後立刻)及再次在給藥第3天(2.5 mg)及第4天(5 mg)評估站立BP及起立性評估後立即給藥後6至8小時之間,採集用於評估研究化合物血漿濃度之血樣。個體已達到停止標準後或在劑量遞增順序結束時,在最後一次投藥24小時後採集一個其他PK樣本。 在部分B中,在給藥前(給藥前30分鐘內),在給藥後6至8小時間(單一時間點)及給藥後24小時,採集用於PK之血樣。適宜地,在評估BP及起立性評估之後採集所有PK樣本。記錄每次血液收集之實際收集時間。 在部分C中,在第1天及第2天給藥前30分鐘收集血樣及在第1天給藥後6至9小時間再次採集。亦可在患者來診所時採集血樣。 4.藥效動力學 (PD) 評估
在部分A中,在給藥第1天(安慰劑)、第3天(2.5 mg)及第4天(5 mg),在包括給藥前兩次(在給藥前30分鐘內及在每次評估仰臥及站立BP及起立性評估後不久)之時間點及再次於給藥後6至8小時間(在評估站立BP及起立性評估後不久)採集用於分析NE及二羥基苯基二醇(DHPG)之血樣。在給藥後24小時(仰臥及站立),在最後一次給藥後,在個體已達到停止標準或在劑量遞增順序結束時,採集兩個其他PD樣本。 在部分B中,在給藥第1天,在包括給藥前兩次(在給藥前30分鐘內及在每次評估仰臥及站立BP及起立性評估後立刻)之時間點及再次於給藥後6至8小時間(在評估站立BP及起立性評估後不久)採集用於分析NE及DHPG之血樣。 在部分C中,在第1天及第2天給藥前30分鐘及再次於第1天給藥後6至9小時間採集血樣。亦可在患者來診所時採集血樣。F. 研究終點
就部分A及B而言,主要研究終點為與藥物投與後6至8小時時坐式收縮壓之安慰劑之差異。就部分A而言,安慰劑係指第1天隨訪,及與安慰劑之差異係指每一研究化合物給藥日(第2天至第5天)相對安慰劑給藥(第1天)之時間匹配差異。就部分C而言,主要研究終點為李克特量表(Likert scale)中第4週時「頭暈、頭痛、暈厥或感覺快要漆黑」(OHSA問題1)之改善。 次要終點包括:站立SBP中在給藥後6至8小時時安慰劑改變;李克特量表中第4週時「頭暈、頭痛、暈厥或感覺快要漆黑」(詢問前患者的週平均症狀排名)之改善;其他問卷得分;站立SBP(站立1分鐘時、3分鐘時、5分鐘時及10分鐘時之曲線測量下方面積)之增加;坐位SBP(藥物投與後10小時之曲線下面積)之增加;及起立式站立測試期間之站立之持續時間。 部分A之初步結果顯示於表7中。在表7中,檢驗標記(ü)指示觀察到當患者投與4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶鹽酸鹽時相對安慰劑之劑量相關改善。表7中之所有患者接受部分A中之10 mg/天之最大劑量,但部分A中接受5 mg/天之最大劑量之患者編號5除外。表 7 研究之初步結果 – 部分 A 1
MSA = 多發性系統萎縮症 PAF = 單純性自主神經衰竭 PD+ = 帕金森氏症加上nOH之症狀2
ü = 相對安慰劑所觀測到的與劑量相關之改善。 表7中之數據證實,在完成部分A的患者中,12位患者中有10位(83%)顯示相對安慰劑之以下至少一者之改善:(a)坐式收縮壓;(b)站立時間;或(c)眩暈或頭暈。四位患者(未顯示於表7中)停止部分A或未完全做評估,因為預先存在的臥式高血壓(3位患者)或心房震顫(1位患者)。在完成部分A的MSA患者中,6位患者中6位(100%)顯示相對安慰劑之表7中至少一個類別之改善。
Claims (20)
- 如請求項1之用途,其中該化合物為4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶鹽酸鹽。
- 如請求項1之用途,其中該化合物為4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶之鹽酸鹽結晶,其特徵係包括在4.44±0.20、10.22±0.20、17.16±0.20及21.78±0.20之2θ值處之繞射峰之粉末x射線繞射圖案。
- 如請求項3之用途,其中該4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶之 鹽酸鹽結晶之另一特徵係在選自8.11±0.20、13.18±0.20、16.06±0.20、18.38±0.20、23.76±0.20、26.32±0.20、27.24±0.20、29.60±0.20及31.94±0.20之2θ值處具有一或多個其他繞射峰。
- 如請求項1之用途,其中該化合物為4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶之鹽酸鹽結晶,其特徵係具有約197±2℃之熔點之差示掃描量熱法跡線(differential scanning calorimetry trace)。
- 如請求項1之用途,其中該患者罹患多發性系統萎縮症。
- 如請求項1之用途,其中該化合物係以在約1mg/天至約10mg/天範圍內的量投與。
- 如請求項1之用途,其中投與該化合物至該患者增加該患者坐式收縮壓。
- 如請求項1之用途,其中投與該化合物至該患者增加該患者站立時間。
- 如請求項1之用途,其中投與該化合物至該患者減少該患者所經歷之暈眩或頭暈。
- 如請求項11之用途,其中該化合物為4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶鹽酸鹽。
- 如請求項11之用途,其中該化合物為4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶之鹽酸鹽結晶,其特徵係包括在4.44±0.20、10.22±0.20、17.16±0.20及21.78±0.20之2θ值處之繞射峰之粉末x射線繞射圖案。
- 如請求項13之用途,其中該4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶之鹽酸鹽結晶之另一特徵係在選自8.11±0.20、13.18±0.20、16.06±0.20、18.38±0.20、23.76±0.20、26.32±0.20、27.24±0.20、29.60±0.20及31.94±0.20之2θ值處具有一或多個其他繞射峰。
- 如請求項11之用途,其中該化合物為4-[2-(2,4,6-三氟苯氧基甲基)苯基]哌啶之鹽酸鹽結晶,其特徵係具有約197±2℃之熔點之差示掃描量熱法跡線。
- 如請求項11之用途,其中該患者罹患多發性系統萎縮症。
- 如請求項11之用途,其中該組合物係以足以提供約1mg/天至約10mg/天之該化合物的量投與。
- 如請求項11之用途,其中投與該組合物至該患者增加該患者坐式收縮壓。
- 如請求項11之用途,其中投與該組合物至該患者增加該患者站立時間。
- 如請求項11之用途,其中投與該組合物至該患者減少該患者所經歷暈眩或頭暈。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662381114P | 2016-08-30 | 2016-08-30 | |
US62/381,114 | 2016-08-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201811329A TW201811329A (zh) | 2018-04-01 |
TWI731153B true TWI731153B (zh) | 2021-06-21 |
Family
ID=59772789
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW106129248A TWI731153B (zh) | 2016-08-30 | 2017-08-29 | 用於治療神經性起立性低血壓之化合物 |
Country Status (20)
Country | Link |
---|---|
US (1) | US10238642B2 (zh) |
EP (1) | EP3506900A1 (zh) |
JP (4) | JP6853345B2 (zh) |
KR (1) | KR102054208B1 (zh) |
CN (3) | CN115813923A (zh) |
AU (1) | AU2017321016B2 (zh) |
BR (1) | BR112019003201A2 (zh) |
CA (1) | CA3032168C (zh) |
CL (1) | CL2019000377A1 (zh) |
CO (1) | CO2019001137A2 (zh) |
IL (1) | IL288194B2 (zh) |
MX (1) | MX370970B (zh) |
MY (1) | MY194181A (zh) |
NZ (1) | NZ750392A (zh) |
PH (1) | PH12019500252A1 (zh) |
RU (1) | RU2723095C1 (zh) |
SG (1) | SG11201901477PA (zh) |
TW (1) | TWI731153B (zh) |
WO (1) | WO2018044667A1 (zh) |
ZA (1) | ZA201900640B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2742114C (en) | 2008-11-14 | 2016-09-13 | Theravance, Inc. | Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound |
EP3784655B1 (en) | 2018-06-01 | 2023-10-04 | Theravance Biopharma R&D IP, LLC | Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid |
WO2020191052A1 (en) * | 2019-03-19 | 2020-09-24 | Cerecor, Inc. | Methods for treating symptomatic orthostatic hypotension |
CA3180948A1 (en) * | 2020-06-02 | 2021-12-09 | Mohamed Hussein Hamdan | Sublingual formulation for hypotension and syncope |
WO2023192290A1 (en) | 2022-03-28 | 2023-10-05 | Theravance Biopharma R&D Ip, Llc | Ampreloxetine for use for treating multiple system atrophy |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56104815A (en) | 1980-01-23 | 1981-08-20 | Sumitomo Chem Co Ltd | Remedy for peripheral orthostatic hypotension |
WO2000056319A1 (en) | 1999-03-19 | 2000-09-28 | Knoll Pharmaceutical Company | Treatment of orthostatic hypotension |
WO2008112773A2 (en) | 2007-03-12 | 2008-09-18 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of neurally mediated hypotension |
CA2742114C (en) * | 2008-11-14 | 2016-09-13 | Theravance, Inc. | Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound |
US20130197090A1 (en) | 2012-01-31 | 2013-08-01 | Chelsea Therapeutics, Inc. | Postural stability and incident functions in patients |
WO2014174425A2 (en) * | 2013-04-24 | 2014-10-30 | Mahesh Kandula | Compositions and methods for the treatment of orthostasis and neurological diseases |
MX2016000219A (es) * | 2013-07-08 | 2016-05-31 | Auspex Pharmaceuticals Inc | Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos. |
-
2017
- 2017-08-24 RU RU2019109201A patent/RU2723095C1/ru active
- 2017-08-24 EP EP17761725.5A patent/EP3506900A1/en active Pending
- 2017-08-24 CN CN202211404261.0A patent/CN115813923A/zh active Pending
- 2017-08-24 MY MYPI2019000101A patent/MY194181A/en unknown
- 2017-08-24 CN CN202211332857.4A patent/CN115770244A/zh active Pending
- 2017-08-24 WO PCT/US2017/048324 patent/WO2018044667A1/en unknown
- 2017-08-24 SG SG11201901477PA patent/SG11201901477PA/en unknown
- 2017-08-24 CA CA3032168A patent/CA3032168C/en active Active
- 2017-08-24 IL IL288194A patent/IL288194B2/en unknown
- 2017-08-24 BR BR112019003201A patent/BR112019003201A2/pt active Search and Examination
- 2017-08-24 US US15/685,119 patent/US10238642B2/en active Active
- 2017-08-24 AU AU2017321016A patent/AU2017321016B2/en active Active
- 2017-08-24 NZ NZ750392A patent/NZ750392A/en unknown
- 2017-08-24 MX MX2019001915A patent/MX370970B/es active IP Right Grant
- 2017-08-24 CN CN201780051586.6A patent/CN109640989A/zh active Pending
- 2017-08-24 KR KR1020197009073A patent/KR102054208B1/ko active IP Right Grant
- 2017-08-24 JP JP2019511563A patent/JP6853345B2/ja active Active
- 2017-08-29 TW TW106129248A patent/TWI731153B/zh active
-
2019
- 2019-01-30 ZA ZA201900640A patent/ZA201900640B/en unknown
- 2019-02-04 PH PH12019500252A patent/PH12019500252A1/en unknown
- 2019-02-07 CO CONC2019/0001137A patent/CO2019001137A2/es unknown
- 2019-02-13 CL CL2019000377A patent/CL2019000377A1/es unknown
- 2019-10-21 JP JP2019192017A patent/JP2020023552A/ja not_active Withdrawn
-
2021
- 2021-07-16 JP JP2021118135A patent/JP2021167344A/ja not_active Withdrawn
-
2023
- 2023-08-31 JP JP2023141033A patent/JP2023159438A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI731153B (zh) | 用於治療神經性起立性低血壓之化合物 | |
JP2022105159A (ja) | 統合失調症を治療するための2-((1-(2(4-フルオロフェニル)-2-オキソエチル)ピペリジン-4-イル)メチル)イソインドリン-1-オン | |
US20230257363A1 (en) | Compounds, compositions and methods | |
US20110200687A1 (en) | Bifeprunox mesylate maintenance dose compositions and methods for using the same | |
RU2775772C2 (ru) | Норадренергический и специфически серотонинергический анксиолитик и антидепрессант, способ его получения и применения | |
EP4137208A1 (en) | Noradrenergic and specific serotonergic anxiolytic and antidepressant, and method for producing same and using same | |
US20230372318A1 (en) | Methods for treating a subject having multiple system atrophy |